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The global response to viral hepatitis entered 
a new phase in 2015, when the UN General 
Assembly adopted the 2030 Agenda for Sustainable 
Development, which called on the international 
community to combat hepatitis. The following year, 
the World Health Assembly adopted WHO’s fi rst 
“Global Health Sector Strategy on viral hepatitis”, 
with elimination as its overarching vision.
The Global hepatitis report, 2017 provides a baseline 
for the drive towards elimination. It sets out global 
statistics on viral hepatitis B and C, the rate of new 
infections, the prevalence of chronic infections and 
mortality caused by these two high-burden hepatitis 
viruses, as well as coverage levels of key interventions, 
as at the end of 2015.
As these statistics reveal, viral hepatitis is a major 
public health challenge that requires an urgent 
response. The disease caused 1.34 million deaths in 
2015, a number comparable to annual deaths caused 
by tuberculosis and higher than those caused by HIV. 
While mortality from HIV, tuberculosis, and malaria 
is now declining, mortality caused by viral hepatitis is 
on the rise. The report provides guidance on how to 
reverse this alarming trend, describing a number of 
high-impact interventions and opportunities for 
their scaled-up implementation. 
We have good evidence that eliminating viral 
hepatitis is technically feasible. Many countries have 
achieved outstanding coverage with the hepatitis B 
vaccine, scoring an early win for prevention. 
The recent development of highly eﬀ ective direct-
acting antivirals, with cure rates exceeding 95%, 
has revolutionized the treatment of chronic hepatitis 
C infections. Most countries have also made 
good progress in keeping blood supply safe and 
improving injection safety in health-care settings, 
substantially reducing the risk of both hepatitis B 
and C virus infections. 
However, a large number of people – about 325 million 
worldwide in 2015 – are carriers of hepatitis B or C 
virus infections, which can remain asymptomatic for 
decades. Each year, 1.75 million people newly acquire 
hepatitis C virus infection. These people are at risk of 
a slow progression to severe liver disease and death, 
unless they receive timely testing and treatment. 
Unfortunately, access to aﬀ ordable care is disturbingly 
low, as highlighted in the report.
The world has only recently expressed its alarm about 
the burden of viral hepatitis. The response is still at 
an early phase in most countries, which limits the 
reliability and scope of available data. At the same 
time, some countries have taken groundbreaking 
actions to combat the epidemic, with results that 
bring encouragement everywhere. 
I urge all countries to seize the opportunities set out in 
this report to eliminate viral hepatitis as a public health 
threat by 2030. Doing so will free the world from what 
we now know is a leading killer worldwide. 
Dr Margaret Chan
WHO Director-General
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EXECUTIVE SUMMARY
In May 2016, the World Health Assembly endorsed 
the Global Health Sector Strategy (GHSS) on viral 
hepatitis 2016–2021. The GHSS calls for the 
elimination of viral hepatitis as a public health 
threat by 2030 (reducing new infections by 90% 
and mortality by 65%). 
This WHO Global hepatitis report describes, for 
the fi rst time, the global and regional estimates 
on viral hepatitis in 2015, setting the baseline 
for tracking progress in implementing the 
new global strategy. 
The report focuses on hepatitis B and C, which 
are responsible for 96% of all hepatitis mortality. 
It presents data along the fi ve strategic directions 
(strategic information, interventions, equity, 
fi nancing and innovation) – key pillars of the GHSS 
to facilitate monitoring of progress in countries, 
regions and globally, and to measure the impact 
of interventions on reducing new infections and 
saving lives between 2015 and 2030. 
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VIRAL HEPATITIS IS A MAJOR PUBLIC HEALTH PROBLEM IN NEED OF AN URGENT RESPONSE.
VACCINATION DRAMATICALLY REDUCED NEW HBV INFECTIONS AMONG CHILDREN, BUT OTHER 
HBV AND HCV PREVENTION INTERVENTIONS HAVE NOT BEEN IMPLEMENTED SUFFICIENTLY.
A LARGE BURDEN OF CHRONIC INFECTIONS AMONG ADULTS CALLS FOR GREATER 
ACCESS TO TESTING AND TREATMENT.
Viral hepatitis caused 1.34 million deaths in 2015, a number comparable 
to deaths caused by tuberculosis and higher than those caused by HIV. 
However, the number of deaths due to viral hepatitis is increasing over 
time, while mortality caused by tuberculosis and HIV is declining. Most 
viral hepatitis deaths in 2015 were due to chronic liver disease (720 000 
deaths due to cirrhosis) and primary liver cancer (470 000 deaths due to 
hepatocellular carcinoma). Globally, in 2015, an estimated 257 million 
people were living with chronic HBV infection, and 71 million people 
with chronic HCV infection. The epidemic caused by HBV affects mostly 
the WHO African Region and the Western Pacifi c Region. The epidemic 
caused by HCV affects all regions, with major differences between and 
within countries. The WHO Eastern Mediterranean Region and the 
European Region have the highest reported prevalence of HCV.
An early win in the global response to viral hepatitis was achieved through 
the effective scaling up of hepatitis B vaccine. In 2015, global coverage 
with the three doses of hepatitis B vaccine in infancy reached 84%. 
This has substantially reduced HBV transmission in the fi rst fi ve years 
of life, as refl ected by the reduction in HBV prevalence among children 
to 1.3%. However, coverage with the initial birth dose vaccination is still 
low at 39%. Other prevention interventions are available but insuffi ciently 
implemented. Although injection drug use is the major route of HCV 
transmission in some regions, the provision of effective harm reduction 
services has been inadequate. Globally, 5% of health-care-related injections 
remained unsafe. As a result, an estimated 1.75 million new HCV infections 
occurred worldwide in 2015.
Access to affordable hepatitis testing is limited. Few people with viral 
hepatitis have been diagnosed (9% of HBV-infected persons, 22 million, 
and 20% of HCV-infected persons, 14 million). Among those diagnosed, 
treatment has reached only a small fraction. In 2015, 8% of those diagnosed 
with HBV infection or 1.7 million persons were on treatment, while 7.4% 
of those diagnosed with HCV infection or 1.1 million persons had started 
treatment. While the cumulative number of persons treated for HCV 
reached 5.5 million in 2015, only about half a million of these persons had 
received the newer, more effective and better tolerated class of drugs called 
direct-acting antivirals (DAAs). There were more new HCV infections 
than patients who were started on treatment in 2015. 
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ix
 “EARLY ADOPTER” COUNTRIES ARE ON THE ROAD TO ELIMINATING VIRAL HEPATITIS. 
OPPORTUNITIES FOR IMMEDIATE ACTION EXIST: FOR EXAMPLE, THROUGH EXPANDED 
TREATMENT FOR PEOPLE WITH HIV WHO ARE COINFECTED WITH HBV OR HCV.
THE ROAD TO ELIMINATION BY 2030 REQUIRES A COMPREHENSIVE PUBLIC HEALTH 
APPROACH TAKEN TO SCALE.
Several “early adopter” countries are showing that rapid scale up of testing 
and treatment can be achieved through committed political leadership, and 
a reduction in the prices of essential medicines and diagnostics to expand 
testing and treatment services. First-line tests for the diagnosis of viral 
hepatitis are available for as little as US$ 0.5. The most effective hepatitis 
B treatment – tenofovir – is available for US$ 48 per year. Hepatitis C 
can be cured within 2–3 months with highly effective DAAs, and in some 
countries a full course of generic DAAs can be accessed for only US$ 200. 
Among the 36.7 million persons living with HIV in 2015, an estimated 2.7 
million had chronic HBV infection and 2.3 million had been infected with 
HCV. Liver diseases are a major cause of morbidity and mortality among 
those living with HIV and coinfected with viral hepatitis. These people 
should be diagnosed and provided with appropriate and effective treatment 
for both HIV and hepatitis as a priority. 
The information contained in this global report can guide countries and 
global partners on the road to elimination of viral hepatitis. First, a strategic 
information system based on surveillance and programme data is needed 
to direct policy change and implementation. Second, service coverage 
of testing and treatment needs to be rapidly scaled up. Third, hepatitis 
services need to be delivered through a public health approach to benefi t all. 
Fourth, sustainable fi nancing is required to enable universal health coverage, 
the overarching framework for health in the 2030 Agenda for Sustainable 
Development. Fifth, innovations are necessary; new diagnostics, treatments, 
cure and vaccines need to be developed, tested and delivered urgently to 
transform the hepatitis response and attain the elimination targets. 
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01
INTRODUCTION: 
SETTING THE BASELINE FOR 
ELIMINATION OF HEPATITIS 
01 – Field investigations in Mongolia
1Public health activities to control viral hepatitis have progressively increased over the past three 
decades. In the 1990s, the World Health Assembly fi rst 
recommended the inclusion of hepatitis B vaccine in 
routine infant immunization schedules. Hepatitis B 
vaccine given shortly after birth prevents HBV infection 
that occurs early in life. HBV infection acquired during 
infancy carries a greater risk of death later in life from 
cirrhosis and hepatocellular carcinoma (1). Coverage 
of immunization against HBV increased from the 
early 2000s with support from the Global Alliance for 
Vaccines and Immunization (GAVI, now known as the 
Vaccine Alliance) (1), and optimized procurement in 
the American Region through the revolving fund.
From the 2000s, iterations of the Global Burden of 
Disease (GBD) project improved estimations of the 
real burden of mortality from viral hepatitis. It then 
became clear that cirrhosis and hepatocellular carcinoma 
accounted for the majority of the burden from viral 
hepatitis (2). Prevention interventions progressed further, 
with initiatives on blood safety (3), health-care injection 
safety (4), infection control, and harm reduction for 
people who inject drugs. However, the early medications 
for the treatment of viral hepatitis B and C had limited 
effectiveness, and were poorly tolerated and expensive. 
This lack of treatment options meant that little or no 
progress was made in the management of people with 
chronic hepatitis infection.
By 2010, there was growing public awareness of the 
public health burden of viral hepatitis. However, there 
were major gaps in the response and mortality was 
increasing. In 2010, the World Health Assembly adopted 
the fi rst resolution on viral hepatitis (5), which led to the 
establishment of WHO’s Global Hepatitis Programme 
in 2011. Research and development led to new 
revolutionary treatments for HCV infection, which 
improved treatment outcomes. A second resolution 
in 2014 (6) further underlined the public health 
importance of viral hepatitis, and raised the possibility 
of elimination of HBV and HCV.
Five viruses are responsible for most cases of viral hepatitis, which 
is an infl ammation of the liver due to a viral infection. These are 
the hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus 
(HCV), hepatitis D virus (HDV) and hepatitis E virus (HEV). All the 
hepatitis viruses can cause acute hepatitis. However, only HBV, 
HCV and HDV frequently cause chronic hepatitis, which can lead to 
progressive scarring of the liver (cirrhosis) and to primary liver cancer 
(hepatocellular carcinoma). Of these, HBV and HCV cause 96% of the 
mortality from viral hepatitis and are therefore the main focus of this 
report (although for some of the deaths from HBV infection, HDV 
may also be a cofactor).
In May 2016, the World Health Assembly adopted 
the Global Health Sector Strategy (GHSS) on viral 
hepatitis for 2016–2021. It has fi ve strategic directions: 
(i) information for focused action; (ii) interventions 
for impact; (iii) delivering for equity; (iv) fi nancing for 
sustainability; and (v) innovation for acceleration (7). 
The 194 Member States of WHO committed to 
eliminating viral hepatitis as a public health threat by 
2030 (defi ned as a 65% reduction in mortality and a 90% 
reduction in incidence compared with the 2015 baseline) 
(7). Elimination can be achieved through suffi cient service 
coverage of fi ve synergistic prevention and treatment 
interventions. These are (i) immunization against hepatitis 
B, (ii) prevention of mother-to-child transmission of 
HBV, (iii) blood and injection safety, (iv) prevention of 
transmission of HBV and HCV among persons who inject 
drugs through comprehensive harm reduction services, 
and (v) testing and treatment. WHO also developed a 
monitoring and evaluation framework for the GHSS 
on viral hepatitis (8). 
This report provides an update on the epidemiological 
situation and response to the HBV and HCV epidemics 
globally, and in each of WHO’s six regions in 2015. 
It provides baseline data for monitoring the 
implementation and impact of the GHSS on viral 
hepatitis, and uses selected examples from countries. 
It highlights areas of uncertainty and calls for more 
evidence where information is lacking.
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2First ever 
Harm Reduction 
International 
Conference
First WHO 
Resolution 
on hepatitis B 
vaccine
Launch of WHO’s 
Safe Injection Global 
Network (SIGN)
The fi rst HBV 
vaccines funded 
by GAVI
First World 
Health Assembly 
Resolution on 
viral hepatitis – 
World Hepatitis 
Day an oﬃ  cial 
WHO day
Civil society advocacy – 
World Hepatitis Alliance 
establishes oﬃ  cial 
relations with WHO.
WHO publishes 
Guidance on 
prevention of HBV 
and HCV infection 
among PWID.
World Hepatitis Alliance 
and WHO launch the 
Global policy report 
on the prevention and 
control of viral hepatitis.
WHO Director-General 
forms fi rst Hepatitis 
Scientifi c and Technical 
Advisory Committee (STAC).
WHO prequalifi es the fi rst 
enzyme immunoassay (EIA) 
for detection of HBsAg.
Global Burden of Disease - 
mortality burden from viral 
hepatitis is fi rst documented.
First World Blood 
Donor Day
First Strategic Advisory 
Group of Experts (SAGE) 
recommendation for 
timely birth dose
Global Hepatitis 
Programme established 
at WHO following WHA 
resolution 63.18
A cure is developed 
– the fi rst direct-
acting antivirals 
revolutionize 
hepatitis C 
treatment.
WHA67.6 resolution 
asks countries to 
develop national 
plans and to include 
civil society and asks 
WHO “to examine the 
feasibility of elimination 
of HBV and HCV with a 
view to setting targets”.
WHO publishes 
Guidelines for the 
prevention, care and 
treatment of persons 
with chronic hepatitis C 
infection.
TIMELINE – TOWARDS THE 
ELIMINATION OF VIRAL HEPATITIS
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PREVENTION BEGINS PREVENTION IS 
STRENGTHENED 
AND TREATMENT 
IMPROVED
1990
1992
1999
2001
2010
2012
2013
2014
2000
2004
2011
2013
2014
3Glasgow 
Declaration from 
the fi rst World 
Hepatitis Summit
NOhep launched on 
World Hepatitis Day
Plan of Action for 
the Prevention and 
Control of Viral 
Hepatitis 2016–2019 
in the Region of the 
Americas approved 
by Member States
Regional Action Plan for Hepatitis 
in the South-East Asia Region 
approved by Member States
Joint society statement for 
elimination of viral hepatitis – 
EASL, APASL, ALEH and AASLD
Regional Action Plan 
for Viral Hepatitis in the 
European Region approved 
by Member States
Regional Action Plan for the 
Implementation of the Global 
Strategy for Viral Hepatitis 
2017–2021 for the Eastern 
Mediterranean Region 
approved by Member States
First global 
hepatitis 
report with 
WHO-validated 
estimates
WHO prequalifi es 
the fi rst EIA for 
detection of HCV 
antibodies.
The Regional Action Plan for 
Viral Hepatitis in the Western 
Pacifi c 2016–2020 approved by 
Member States 
A Framework for Action 2016–
2020 for the prevention, care 
and treatment of viral hepatitis 
in the African Region approved 
by Member States
WHO prequalifi es the 
fi rst HCV rapid test.
Adoption of fi rst global health sector 
strategy on viral hepatitis “Towards 
ending viral hepatitis”, 2016–2021. 
Eliminate viral hepatitis as a major 
public health threat by 2030. 
First WHO 
Guidelines on 
hepatitis B and C 
testing
First-ever WHO Global report on access to 
hepatitis C treatment showed over 1 million 
persons treated with DAA-based regimens in 
low- and middle-income countries.
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GLOBAL ACTION
SEPTEMBER
2015
JULY
2016
OCTOBER
2016
APRIL
2017
APRIL
2016
SEPTEMBER
2016
JUNE
2015
OCTOBER
2015
AUGUST
2016
MAY
2016
NOVEMBER
2016
FEBRUARY
2017
First update of hepatitis C treatment 
guidelines with fi rst-ever preferred 
and alternative direct-acting antiviral 
(DAA)-based regimen recommended
UN General Assembly Special 
Session on Drugs 
402 – Transmission of HBV from mother to child most 
often leads to chronic liver disease.
5HEPATITIS A VIRUS – HAV
Hepatitis A causes only acute hepatitis. HAV is transmitted mostly through 
exposure to contaminated food or water, or through exposure to infected persons. 
A safe and effective vaccine is available. WHO estimates that worldwide, hepatitis A 
caused approximately 11 000 deaths in 2015 (accounting for 0.8% of the mortality 
from viral hepatitis) (9).
HEPATITIS D VIRUS – HDV
Hepatitis D is caused by an incomplete virus, HDV. It is transmitted mostly 
through the percutaneous route (exposure to blood). HDV infects only those 
persons who already have HBV infection. Infection of an HBV-infected person with 
HDV (a phenomenon referred to as “superinfection”) worsens the outcome of HBV 
infection. Hence, HDV is a cofactor of chronic liver disease. Most experts estimate 
that 5% of HBV-infected persons are also coinfected with HDV (10). However, 
there is substantial uncertainty, as in many countries, HBV-infected patients are 
not tested for HDV infection. In addition, in selected countries, such as Mongolia, 
up to 60% of HBV-infected persons may also have HDV infection (11). Prevention 
of HBV infection through vaccination also prevents HDV infection. However, the 
treatment of HBV–HDV-coinfected patients differs from the treatment of persons 
with HBV infection alone. Newer antinucleos(t)ides that are highly effective 
against HBV infection do not work well in HBV–HDV coinfection. Only older, 
interferon-based treatments can be used, with suboptimal results. WHO does 
not have estimates of the proportion of deaths due to HBV in which HDV may 
be a cofactor (12). The distribution of HDV infection varies around the world.
HEPATITIS E VIRUS – HEV
HEV causes mostly acute hepatitis. It is transmitted via the faecal–oral route, 
principally via contaminated water. Every year, there are an estimated 20 million 
HEV infections worldwide, leading to an estimated 3.3 million symptomatic cases 
of acute hepatitis E (13). WHO estimates that hepatitis E caused approximately 
44 000 deaths in 2015 (accounting for 3.3% of the mortality due to viral hepatitis). 
Hepatitis E is a usually self-limiting illness, but some patients may progress to acute 
liver failure. Hepatitis E has a higher case fatality in pregnant women. This leads 
to maternal mortality that is particularly devastating. Infection with HEV is 
reported worldwide, but it is most common in East and South Asia. A vaccine to 
prevent HEV infection has been developed and is licensed in China, but is not 
yet available in most other countries (14).
BEYOND THE SCOPE OF THE REPORT: 
HEPATITIS A, D AND E
INTRODUCTION
02
EPIDEMIOLOGICAL UPDATE: 
INCREASING MORTALITY 
CALLS FOR ACTION 
03 – Intensive care unit for patients 
with liver disease, India.
7HBV
NEW INFECTIONS IN 2015
•  The widespread use of hepatitis B 
vaccine in infants has considerably 
reduced the incidence of new chronic 
HBV infections. Between the pre-
vaccine era (which, according to the 
year of introduction can range from the 
1980s to the early 2000s) and 2015, the 
proportion of children under 5 years of 
age who became chronically infected 
fell from 4.7% to 1.3%. The remaining 
infections mostly occur from the 
mother at birth or through contact 
with other infected young children.a 
CHRONIC INFECTIONS IN 2015
 •  WHO estimates that in 2015, 
257 million persons, or 3.5% of the 
population, were living with chronic HBV 
infection in the world. The African and 
Western Pacifi c regions accounted 
for 68% of those infected.
 •  2.7 million persons were coinfected 
with HBV and HIV.
 •  Most of the people currently living with 
HBV infection are persons born before 
hepatitis B vaccine was widely available 
and used in infancy.
HCV
NEW INFECTIONS IN 2015 
 •  Unsafe health-care procedures and 
injection drug use were the leading 
causes of new HCV infections, 
accounting for most of the 1.75 million 
new infections in 2015. 
KEY FINDINGS
CHRONIC INFECTIONS IN 2015 
 •  WHO estimates that in 2015, 71 million 
persons were living with HCV infection 
in the world, accounting for 1% of 
the population.
 •  2.3 million persons living with HIV also 
had HCV infection.
 •  HCV infection is unevenly distributed 
in the world. The European and 
Eastern Mediterranean regions 
are more aﬀ ected, but there are 
variations in prevalence across and 
within countries.
MORTALITY IN 2015
 •  WHO estimates that in 2015, viral 
hepatitis was responsible for 1.34 
million deaths. This number was 
comparable with the number of 
deaths from tuberculosis, but 
higher than the number of deaths 
from HIV. 
 •  Left untreated, HBV and HCV infection 
can lead to cirrhosis (720 000 deaths) 
and hepatocellular carcinoma 
(470 000 deaths). These long-term 
complications are life-threatening 
and accounted for 96% of the deaths 
due to viral hepatitis. 
 •  Mortality from viral hepatitis has 
increased by 22% since 2000. Unless 
people with HBV and HCV infection are 
diagnosed and treated, the number 
of deaths due to viral hepatitis will 
continue to increase. 
a  The WHO monitoring and evaluation framework for viral hepatitis B and C recommends monitoring the cumulative incidence of chronic HBV 
infections in children 5 years of age, as most persons infected later in life do not develop life-threatening complications of HBV infection.
EPIDEMIOLOGICAL UPDATE: INCREASING MORTALITY CALLS FOR ACTION
8UNDERSTANDING THE VIRAL HEPATITIS EPIDEMIC: 
THE FIRST STEP TOWARDS ELIMINATION 
A LATENT PERIOD BETWEEN INFECTION AND DEATH
Persons infected with HBV or HCV are usually unaware of their 
infection, as they do not have well-defi ned symptoms before 
complications emerge. The natural history of HBV and HCV 
infection progresses through three stages.
New infections. After infection with HBV or HCV, a small subset of 
people may develop acute hepatitis. However, in most persons, this new 
infection goes unnoticed as it produces no symptoms. These new infections 
may then evolve into chronic infections. Incidence can be defi ned as 
the rate of occurrence of new infections. It is reported as the number of 
new infections in the population over a given period of time. Incidence 
measures the risk of contracting the infection and refl ects transmission. 
Chronic infection. Some new infections can evolve into chronic infections 
while others evolve towards spontaneous clearance of the virus. The risk 
of developing chronic infection with HBV is highest among children, 
whereas infection with HCV becomes chronic in most infected persons.a 
A person may be infected with HBV or HCV for as long as 30 years or 
more before they develop any clinical symptoms of disease. Unless persons 
are tested and diagnosed, they are not aware of their disease. However, 
hidden infl ammation progresses in the liver. Prevalence is the proportion 
of a population infected at a given time.
Mortality. Untreated chronic viral hepatitis can progress to life-threatening 
complications. Depending on life expectancy, 20% or more of those with 
chronic infection develop end-stage chronic liver disease, such as cirrhosis 
or hepatocellular carcinoma. Cofactors (e.g. alcohol, HIV infection) 
can accelerate progression towards end-stage liver disease. Cirrhosis 
and hepatocellular carcinoma are life-threatening conditions.
01
02
03
a  HCV not only aﬀ ects the liver; it can also cause chronic fatigue, autoimmune 
conditions, renal diseases and lymphomas.
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9ELIMINATING VIRAL HEPATITIS AS A PUBLIC 
HEALTH THREAT
The burden of viral hepatitis constitutes a 
public health threat in many areas of the world. 
In 2016, the World Health Assembly approved 
a global strategy to achieve elimination of this 
public health threat by 2030. To do this, and 
starting from the 2015 baseline, countries and 
regions need to reduce new infections (incidence) 
by 90%a and reduce deaths (mortality) by 
65% by 2030.
FIRST FIVE YEARS OF LIFE – A CRITICAL TIME 
TO PREVENT HBV INFECTION
Most of the burden of disease from HBV infection 
comes from infections acquired before the age of 5 
years (15). Therefore, prevention of HBV infection 
focuses on children under 5 years of age. The United 
Nations selected the cumulative incidence of chronic 
HBV infection at 5 years of age as an indicator of the 
Sustainable Development Goal target for “combating 
hepatitis” (16). This indicator is measured indirectly 
through the proportion of children 5 years of age 
who have developed chronic HBV infection (i.e. the 
proportion that tests positive for a marker of infection 
called hepatitis B surface antigen [HBsAg]).
Infants born to untreated HBV-infected mothers can 
acquire infection from the mother, mostly during birth. 
Infants born to mothers who are positive for both HBsAg 
and hepatitis B e antigen (HBeAg) are at a higher risk 
of acquiring infection (transmission risk for HBsAg-
positive and HBeAg-positive mothers: 70–100% in Asia 
and 40% in Africa) than those born to HBsAg-positive 
mothers who have lost the HBeAg (5–30% in Asia and 
5% in Africa) (15, 17, 18). Early vaccination of the baby 
against hepatitis B with a fi rst dose within 24 hours of 
birth (timely birth dose) contributes to the prevention of 
mother-to-child transmission. The effi cacy of the vaccine 
decreases with the concentration of HBV in the blood of 
the mother. HBeAg-negative mothers have a near 0% risk 
of transmitting HBV to their offspring vaccinated at birth 
(19), while HBeAg-positive mothers have a 20% risk of 
transmitting the virus despite vaccination at birth (20). 
Treatment of pregnant mothers with antivirals, which 
is being introduced as a new intervention to prevent 
mother-to-child transmission of HBV, should further 
reduce the risks of transmission (21).
Younger age cohorts have a lower incidence 
of chronic HBV infection compared to the 
pre-vaccination era
The low incidence of chronic HBV infection in 
children under 5 years of age at present can be 
attributed to the widespread use of hepatitis B vaccine. 
Worldwide, in 2015, the estimated prevalence of HBV 
infection in this age group was about 1.3% (Table 1), 
compared with about 4.7% in the pre-vaccination era 
(which, according to the year of introduction can range 
from the 1980s to the early 2000s).b 
However, the prevalence was still 3% in the African 
Region. This fall in the incidence of chronic HBV 
infections among children means that in the long term, 
the global hepatitis B epidemic will decline. However, 
deaths among infected adults born before the era of 
vaccination will continue to increase if they are not 
diagnosed and treated.
STATUS OF HEPATITIS B
a  For HBV, a 90% reduction in incidence compared with the 2015 baseline would be 
equivalent to 0.1% prevalence of HBV infection in children fi ve years of age in 2030.
b  Source:  WHO, work conducted by the London School of Hygiene & Tropical 
Medicine (LSHTM), data not shown.
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  Prevalence of HBsAg (%)
          Uncertainty intervals 
WHO region Map key Best Lower Higher 
African Region  3.0 2.0 4.7
Region of the Americas  0.2 0.1 0.5
Eastern Mediterranean Region  1.6 1.2 2.1
European Region  0.4 0.2 0.8
South-East Asia Region  0.7 0.5 1.6
Western Pacifi c Region   0.9 0.6 1.3
Total  1.3 0.9 2.2
Table 1 (with map). Cumulated incidence of chronic HBV infection, 2015 (prevalence of HBsAg in children under 5 years) 
after the use of the vaccine by WHO region: about 1.3% of under-5 children have developed chronic HBV infection
Source:  WHO, work conducted by the London School of Hygiene & Tropical Medicine (LSHTM). See Annex 2.
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PREVALENCE OF CHRONIC HBV INFECTION: 
MAJOR EPIDEMICS IN THE AFRICAN AND WESTERN 
PACIFIC REGIONS
Prevalence of HBV infection 
In 2015, the global prevalence of HBV infection in the 
general population was 3.5%. Among those born before 
the hepatitis B vaccine became available, the proportion 
of persons living with chronic HBV infection remains 
high. Prevalence was the highest in the African (6.1%) 
and Western Pacifi c regions (6.2%). Overall, about 
257 million persons were living with HBV infection 
(Table 2). Assuming that women of reproductive age 
constitute 25.3% of the world’s population (United 
Nations data), adults chronically infected may include 
65 million women of childbearing age who can potentially 
transmit HBV to their babies. In addition, a proportion of 
these adults would benefi t from long-term, if not lifelong, 
treatment, particularly those above 30 years of age, those 
who have cirrhosis, and those with HIV infection (22). 
This proportion of patients who would benefi t from 
treatment is not well known. In community-based studies, 
reports range from less than 5% (23) to about 10% (24). 
In health-care facility-based studies, the proportion 
is higher (25). 
04 – Population surveys provide reliable estimates of the 
proportion of the population living with HBV or HCV.
Prevalence of HBV–HIV coinfection 
About 2.7 million (interquartile range: 1.8–3.9) of the 
36.7 million living with HIV are also infected with HBV. 
The global prevalence of HBV infection in HIV-infected 
persons is 7.4%. The prevalence of HBV infection is 
similar across different groups of HIV-infected persons 
and, in particular, between persons without (6.6%) 
or with higher risk behaviours, such as persons who 
inject drugs (7.0%) and men who have sex with men 
(6.1%). Most HIV–HBV-coinfected persons live in 
sub-Saharan Africa (71%; 1.96 million) (26). As HIV-
infected persons continue to live longer due to increased 
uptake of antiretroviral therapy (27), HBV coinfection is 
associated with accelerated progression of chronic hepatitis 
and higher liver-related mortality (26, 28–30). Since 
2015, WHO has recommended treatment for everyone 
diagnosed with HIV infection, regardless of the stage of 
disease (31). However, by the end of 2016, only about 
50% of people with HIV were receiving treatment (32). 
WHO now recommends the use of tenofovir as part 
of fi rst-line treatment for HIV and for the treatment of 
chronic HBV infection, including among pregnant HIV–
HBV-coinfected women. Hence, expansion of tenofovir-
based treatment for HIV will provide effective treatment 
for HBV infection for those who are coinfected with HIV 
and HBV, and will help prevent transmission of HBV 
from mother to child (33). However, data are lacking on 
the actual coverage of tenofovir-based treatment for people 
who are coinfected with HIV and HBV.
 
257
MILLION PERSONS 
WORLDWIDE ARE 
LIVING WITH HBV.
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a  Modelled estimate: 6.6 million, rounded. The WHO Regional Oﬃ  ce for the Americas has worked with its Member States to generate estimates through country 
consultations and modelling. These national estimates were consolidated in 2016 into a regional estimate of 2.8 million people living with chronic HBV infection. 
The diﬀ erence between these estimates is consistent with the diﬀ erent methods used. In addition, low-prevalence settings may lead to lower precision and 
greater uncertainty. WHO headquarters and regional oﬃ  ces will continue to engage in comparative modelling to further understand the source of these 
diﬀ erences. Such analyses should allow more precise consensus estimates in the future. See Annex 2, and (123).
Table 2 (with graph). Prevalence of HBV infection (HBsAg) in the general population by WHO region, 2015: 
the WHO African and Western Pacifi c regions have the highest prevalence and the largest number of persons living with HBV 
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STATUS OF HEPATITIS C
INCIDENCE OF HCV INFECTION: 
TRANSMISSION PERSISTS
Several studies suggest that the incidence of HCV 
infection has decreased since the second half of the 
20th century. First, most countries have age-specifi c 
prevalence of serological evidence of past or present 
infection, suggesting lower incidence in recent years 
(34–37). Second, countries that conduct surveillance 
for acute hepatitis C reported decreases in the rates 
(38). Third, countries that conducted more than one 
biomarker survey, such as Egypt, reported an evolution 
over time that suggests a decrease in incidence (39). 
Fourth, injection safety improved, which reduced the 
incidence of injection-associated HCV infection (40). 
However, estimates obtained from modelling suggest 
that worldwide, in 2015, there were still 1.75 million new 
HCV infections (global incidence rate: 23.7 per 100 000). 
Unsafe health-care practices (including unsafe health-
care injections) and injection drug use remain the leading 
modes of transmission. Areas with high rates of infection 
are located in the Eastern Mediterranean Region (62.5 per 
100 000) and the European Region (61.8 per 100 000). 
In the Eastern Mediterranean Region, the most common 
cause of transmission of infection is unsafe health-care 
injections (41, 42). In the European Region, injection 
drug use accounts for a substantial proportion of new 
infections (Table 3) (43).
Even in areas of the world where the incidence was 
low in 2015, an increase in transmission may occur at 
any time, and through various modes of transmission. 
In the United States of America, for instance, after many 
years of decrease, the incidence of HCV infection doubled 
between 2010 and 2014 (44). The number of reported 
cases of acute hepatitis C among persons reporting 
Source: WHO, work conducted by the London School of Hygiene & Tropical Medicine (LSHTM). See Annex 2.
 Estimates of the  Estimated number of 
 prevalence of HBV infection (%) persons living with HBV (millions)
                         Uncertainty interval (95%)                      Uncertainty interval (95%)
WHO region Best Lower Higher Best Lower Higher 
African Region 6.1 4.6 8.5 60 45 84
Region of the Americas 0.7 0.4 1.6 7a 4 16
Eastern Mediterranean Region 3.3 2.6 4.3 21 17 28
European Region 1.6 1.2 2.6 15 11 23
South-East Asia Region 2.0 1.5 4.0 39 29 77
Western Pacifi c Region  6.2 5.1 7.6 115 93 140
Total 3.5 2.7 5.0 257 199 368
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  Incidence of HCV infection
 Incidence rate (per 100 000)              Total number (000)
WHO region Map key Best  Uncertainty Best  Uncertainty
  estimate interval  estimate interval
African Region  31.0 22.5–54.4 309 222–544
Region of the Americas  6.4 5.9–7.0 63 59–69
Eastern Mediterranean Region  62.5 55.6–65.2 409 363–426
European Region  61.8 50.3–66.0 565 460–603
South-East Asia Region  14.8 12.5–26.9 287 243–524
Western Pacifi c Region   6.0 5.6–6.6 111 104–124
Global  23.7 21.3–28.7 1 751 1 572–2 120
Table 3 (with map). Incidence of HCV infection in the general population, by WHO region, 2015: 
1.75 million new infections in 2015 
Source: WHO, work conducted by the Center for Disease Analysis. See Annex 2.
a  These deaths exclude those from the extrahepatic complications of HCV infection 
and background mortality from other causes among HCV-infected patients.
injection drug use increased, particularly in rural areas 
(45, 46). Injection drug use among young persons results 
in rapid dissemination of HIV and HCV (47), as well as 
some transmission of HBV (48). Transmission of HCV 
has also been reported in Europe, Australia and the USA 
among men who have sex with men (MSM) infected with 
HIV (49). Reinfection has been reported even among 
HIV-infected MSM who were successfully cured with 
treatment for hepatitis C (50). No estimates are available 
to quantify how much this emerging issue contributes 
to the overall transmission of HCV (51, 52).
To determine whether the number of infected persons 
is likely to increase or decrease, the number of new 
HCV infections needs to be compared with the number 
of persons who die and those who are cured. In 2015, 
as the estimated number of persons newly infected 
(N=1.75 million) exceeded the estimated number 
of persons dying from end-stage HCV infection 
(N=399 000)a and being cured (N=843 000), 
the global epidemic may continue to expand in 
magnitude in the absence of scaled-up interventions.
EPIDEMIOLOGICAL UPDATE: INCREASING MORTALITY CALLS FOR ACTION
14
 Estimates of the  Estimated number of 
 prevalence of HCV  infection (%) persons living with HCV (millions)
                                Uncertainty interval                               Uncertainty interval
WHO region Best Lower Higher Best Lower Higher 
African Region 1.0 0.7 1.6 11 7 16
Region of the Americas 0.7 0.6 0.8 7 6 8
Eastern Mediterranean Region 2.3 1.9 2.4 15 13 15
European Region 1.5 1.2 1.5 14 11 14
South-East Asia Region 0.5 0.4 0.9 10 8 18
Western Pacifi c Region  0.7 0.6 0.8 14 10 15
Total 1.0 0.8 1.1 71 62 79
PREVALENCE OF CHRONIC HCV INFECTION: 
UNEVEN GLOBAL EPIDEMIC, WITH DIFFERENCES 
ACROSS AND WITHIN COUNTRIES 
Prevalence of HCV infection
In 2015, 71 million persons were living with chronic HCV 
infection. Compared with HBV, the prevalence of HCV 
infection is lower, but more heterogeneously distributed, 
with differences across and within WHO regions and 
countries. Spread through breaks in infection control 
practices or injection drug use may explain this pattern. 
Overall, in 2015, the global prevalence of HCV infection 
was 1.0%. The Eastern Mediterranean Region had the 
highest prevalence (2.3%) followed by the European 
Region (1.5%) (Table 4).
Table 4 (with graph). Prevalence of HCV infection (HCV RNA positive) in the general population, by WHO region, with uncertainty 
intervals, 2015: 71 million persons living with HCV worldwide 
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71
MILLION PERSONS
WORLDWIDE ARE 
LIVING WITH HCV.
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The proportion of the population living with HCV 
infection often increases with age, in a way that exceeds 
what could be expected from the cumulative risk of 
infection year after year (53). This is often referred to 
as a “cohort effect” and occurs in populations that were 
infected due to factors such as unsafe health-care-related 
injections, which contributed to the transmission of 
HCV on a larger scale earlier (34–36). Of the 71 million 
persons infected with HCV, 5.6 million (8%) currently 
inject drugs. The proportion of current injectors among 
infected persons needs to be taken into account in order 
to provide adapted prevention, care and treatment services 
in an environment free from stigma and discrimination. 
A larger, ill-defi ned proportion of those living with HCV 
are former drug injectors or persons who were infected 
through unsafe health-care-related procedures. Such 
persons access health-care services more easily than 
persons who currently inject drugs (54).
Prevalence of HIV–HCV coinfection
About 2.3 million people (interquartile range: 1.3-4.4) 
of the estimated 36.7 million living with HIV globally 
have serological evidence of past or present HCV infection 
(positive for antibodies to HCV, anti-HCV positive). Of 
these, 1.36 million are persons who currently inject drugs 
(55). Conversely, among all HIV-infected persons, the 
prevalence of anti-HCV was 6.2%. Among HIV-infected 
persons, the prevalence of anti-HCV was highest in 
persons who inject drugs (82.4%), followed by men who 
have sex with men (6.4%), and was much lower in HIV-
infected persons without higher risk behaviours (2.4%). 
Eastern Europe and central Asia account for the largest 
proportion of HIV-infected persons who have serological 
evidence of past or present HCV infection (27%), because 
of injection drug use. HIV coinfection doubles the risk 
of mother-to-child transmission of HCV (56, 57), and is 
associated with less spontaneous HCV clearance, higher 
HCV viral loads, and more rapid progression of liver 
disease (58–61). People living with HIV should 
be tested for HCV infection (54, 62).
05 – Rapid diagnostic tests can be used in a broad range 
of health-care facilities.
PERSONS WITH 
HIV AND HEPATITIS 
SHOULD BE PLACED 
ON EFFECTIVE 
TREATMENT FOR 
BOTH INFECTIONS.
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1.34 MILLION DEATHS: 96% OF THESE ARE DUE TO 
THE SEQUELAE OF HBV AND HCV INFECTION
In 2015, viral hepatitis led to 1.34 million deaths, 
a death toll on a par with those due to tuberculosis 
(1.37 million deaths, without HIV-associated tuberculosis) 
and higher than those due to to HIV (1.06 million deaths) 
or to malaria (0.44 million deaths). Of these deaths, 
96% were the result of complications of chronic HBV 
(66%) and HCV (30%) infections, while hepatitis A 
and hepatitis E accounted for 0.8% and 3.3% of deaths, 
respectively. A proportion of the deaths attributed to 
DEATHS DUE TO VIRAL HEPATITIS ARE 
INCREASING AND WILL CONTINUE TO DO 
SO UNLESS TREATMENT IS SCALED UP
From 2000 to 2015, scaled-up interventions led to a 
decrease in mortality from HIV (from 1.46 to 1.06 
million deaths between 2000 and 2015), tuberculosis 
(from 1.67 to 1.37 million deaths between 2000 and 
2015), and malaria (from 0.86 to 0.44 million deaths 
between 2000 and 2015). In contrast, mortality due to 
viral hepatitis is increasing (Fig. 2). The number of deaths 
rose from 1.10 million deaths in 2000 to 1.34 million 
deaths in 2015 (an increase of 22%).
MORTALITY: DEATHS ATTRIBUTABLE TO VIRAL HEPATITIS 
ARE AS COMMON AS THOSE DUE TO TUBERCULOSIS
HBV infection may be explained by superinfection 
with HDV. Among the long-term complications of 
HBV and HCV infections, cirrhosis (720 000 deaths) 
accounts for more deaths than hepatocellular carcinoma 
(470 000 deaths, Fig. 1). In many patients with end-stage 
HBV or HCV liver disease, the viral infection is not 
mentioned on the death certifi cate when death occurs 
from cirrhosis or hepatocellular carcinoma. In the absence 
of such a link, these deaths are considered as deaths from 
noncommunicable diseases, and the burden of disease 
from viral hepatitis remains underestimated.
Mortality is expected to further increase. For HBV, 
the widespread use of hepatitis B vaccine started in the 
1990s and 2000s. Therefore, those born before this period 
in countries where infection is common would not have 
been vaccinated as children. These unvaccinated birth 
cohorts that have endemicity levels comparable to the 
pre-vaccine era are in their twenties or thirties in Asia 
(63) or in their teenage years in Africa (64). Those who 
were infected are living with HBV and are at risk for 
progression to end-stage liver disease and cancer (1). 
For HCV, the virus was transmitted on a large scale in 
many middle- and low-income countries at the end of the 
20th century, largely due to unsafe health-care procedures 
and injection drug use (65–67). In these countries, 
Fig. 1. Deaths from viral hepatitis, by virus and type of sequelae, 2015: 
most viral hepatitis deaths are due to the late complications of HBV and HCV infection
HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; HEV: hepatitis E virus
Source: WHO global health estimates for 2015 published in 2016 (Global Health Estimates 2015: deaths by cause, age, sex, by country 
and by region, 2000–2015. Geneva: World Health Organization; 2016.) 
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Fig. 2. Global annual mortality from hepatitis, HIV, tuberculosis and malaria, 2000–2015: 
unlike HIV, tuberculosis and malaria, the trend in mortality from viral hepatitis is increasing 
Source: WHO global health estimates (Global Health Estimates 2015: deaths by cause, age, 
sex, by country and by region, 2000-2015. Geneva: World Health Organization; 2016.)
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mortality from the complications of chronic hepatitis C 
infection will continue to increase in the coming 
years if testing and subsequent treatment are not made 
available to those infected. In most high-income 
countries, transmission occurred earlier, just after the 
Second World War (e.g. Japan, Italy and France) (68). 
Although mortality is decreasing the number of persons 
living with HCV today is too small to infl uence the 
global trend.
Sequelae of viral hepatitis kill mostly adults. 
Compared with those less than 30 years of age, persons 
30 years of age and older have a higher mortality rate 
(34.3 per 100 000 versus 2.6 per 100 000) and account 
for a much larger proportion of deaths (93% versus 7%). 
Men have higher mortality rates (23.3 deaths per 
100 000) than women (13.2 deaths per 100 000). 
Regionally, too, there is a difference, with deaths 
from HBV-associated hepatocellular carcinoma 
occurring at a younger age in sub-Saharan Africa 
(median: 38.9 years) than in the Western Pacifi c 
Region (median: 54.5 years) (68).
This results in more years of life lost and greater economic 
loss among Africans. As the age-specifi c rate of incidence 
of hepatocellular carcinoma is not higher in Africa than in 
Asia, this difference in age at death may be explained, in 
part, by a different age pyramid in Africa and Asia, rather 
than by biological factors, such as afl atoxin exposure (69).  
In 2015, as per the United Nations data, the population is 
younger in sub-Saharan Africa (median age: 18.3 years) 
than that in East Asia (median age: 37.9 years).
AFRICA AND ASIA FACE THE LARGEST BURDEN OF 
MORTALITY
The mortality rate from viral hepatitis (18.3 per 
100 000 globally) is highest in the Western Pacifi c Region 
(24.1 deaths per 100 000), followed by the South-East 
Asia Region (21.2 per 100 000) and African Region 
(13.7 per 100 000), and lowest in the American Region 
(11.2 per 100 000). Worldwide, the Western Pacifi c, 
South-East Asia and African regions account for 
446 000, 408 000 and 136 000 deaths, respectively 
(33%, 30% and 10% of the total deaths, respectively).
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THE NUMBER OF COUNTRIES WITH NATIONAL 
POLICIES AND PLANS IS INCREASING 
Globally, there is strong commitment to taking action, 
as refl ected by World Health Assembly resolutions in 
2010 (5) and 2014 (6), and the World Hepatitis Summit 
in September 2015. This was followed in May 2016 with 
endorsement by the World Health Assembly of the Global 
Health Sector Strategy on viral hepatitis for 2016–2021 
(GHSS) (7). As of March 2017, 43 Member States had 
reported to WHO that they had formulated national 
viral hepatitis elimination plans and an additional 
36 Member States reported that they were in the 
process of developing plans.
SURVEILLANCE GUIDES NATIONAL PLANS
Surveillance for viral hepatitis keeps track of the three 
components of the epidemic of HBV and HCV infection 
– acute hepatitis, chronic infections and mortality (70). 
Of these, estimating the prevalence of chronic infection 
in the general population through a biomarker survey 
is key to an initial country assessment (Box 1).
GLOBAL, REGIONAL AND NATIONAL RESPONSES 
TO THE GLOBAL EPIDEMIC OF VIRAL HEPATITIS
BOX 1. CASE STUDY IN IMPROVING STRATEGIC INFORMATION: A BIOMARKER SURVEY TO 
EVALUATE PAST HEPATITIS B IMMUNIZATION EFFORTS AND PLAN TESTING AND TREATMENT, 
BHUTAN, 2016
Most people living with viral hepatitis in the population are asymptomatic. Since these chronic infections 
with HBV and HCV go unnoticed, surveys that collect and test blood specimens are required to estimate 
the number of infected persons. In 1997, Bhutan introduced hepatitis B vaccine in its Expanded Programme 
on Immunization (EPI), and in 2003, 95% coverage was attained. Almost 20 years later, in 2017, Bhutan is 
about to conduct a new national biomarker survey in the general population that will look back to evaluate 
the impact of hepatitis B vaccination on transmission in young children and look ahead to plan the future 
testing and treatment programme for HBV and HCV (see photo). For eﬃ  cient use of resources, this new 
biomarker survey will be integrated with a measles and rubella serological survey.
06 – Participants of a protocol-writing workshop for a hepatitis B and 
hepatitis C biomarker survey in the Kingdom of Bhutan, 2016.
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WHAT SURVEILLANCE SYSTEMS ARE NEEDED 
TO GUIDE AND DOCUMENT ELIMINATION?
This report provides estimates of incidence, prevalence and mortality 
only at the regional level. In many countries, the surveillance systems 
in place do not fully capture the fact that the viral hepatitis epidemic 
is made up of individual infections that evolve through three phases. 
As key information is often missing, each country needs to consider 
three parts of viral hepatitis surveillance:
Surveillance for acute hepatitis, which refl ects new infections. Syndromic 
surveillance (surveillance for clinically defi ned acute hepatitis) is often in place, 
but informs only about outbreaks of hepatitis A or hepatitis E. Enhanced case 
reporting (surveillance for laboratory-confi rmed, type-specifi c viral hepatitis) 
is also needed to describe trends and identify risk factors for infection. 
Information on trends along with repeated estimates of prevalence may 
be used to estimate incidence through modelling. 
Biomarker surveys to estimate the prevalence of chronic infection. 
In countries where the prevalence of HBV or HCV infection is unclear, 
biomarker surveys in the general population may provide baseline estimates 
among adults and evaluate the impact of national vaccination programmes 
among children.a Biomarker surveys among children who were vaccinated 
are used to evaluate impact.
Reliable mortality monitoring. Estimating mortality from HBV and HCV 
infection requires two pieces of information that come from different sources. 
First, national vital statistics and/or cancer registries measure the mortality 
from cirrhosis and hepatocellular carcinoma. Second, health-care facilities 
caring for patients with cirrhosis and hepatocellular carcinoma can estimate the 
proportion of patients with these sequelae who have HBV or HCV infection. 
This proportion can be used along with measures of association to calculate 
the fraction attributable to viral hepatitis. Applying the attributable fraction 
to the national estimates of mortality from cirrhosis and hepatocellular 
carcinoma leads to national estimates of mortality from viral hepatitis. 
01
02
03
a  As regions progress towards elimination of mother-to-child transmission of HBV, 
newer methods will be needed as the sample size needed for biomarker surveys will 
considerably increase as prevalence approaches 0.1%.
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INTERVENTIONS FOR IMPACT: 
EXPANDING PREVENTION, 
TESTING AND TREATMENT
07 – Social mobilization for community-
based testing for HBV infection in Africa.
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PREVENTION
•  In 2015, global coverage with the third 
dose of hepatitis B vaccine reached 
84%, but the European, Eastern 
Mediterranean and African regions 
faced coverage gaps.
•  In 2015, the global coverage with the 
birth dose of hepatitis B vaccine was 
39%. The Region of the Americas and 
Western Pacifi c Region were the only 
regions that had wide coverage.
•  Worldwide, in 2013, 97% of countries 
screened blood donations with quality 
assurance, but gaps persist.
•  Unsafe injections decreased from 
39% in 2000 to 5% in 2010 worldwide. 
However, in the Eastern Mediterranean 
and South-East Asia regions, needles 
and syringes were frequently reused 
without being sterilized.
•  Harm reduction for persons who inject 
drugs falls short of the target of the 
GHSS on viral hepatitis, with on average 
globally only 27 syringe and needle 
sets distributed per person who injects 
drugs each year, as compared with a 
2030 target of 300.
KEY FINDINGS
TESTING IN 2015
 •  Only a minority of those infected 
with HBV and HCV had been tested 
and knew their status: 9% of persons 
living with HBV (22 million) and 20% of 
persons living with HCV (14 million).
TREATMENT IN 2015
 •  Of those diagnosed with HBV 
infection, the proportion on treatment 
with WHO-recommended antivirals 
did not exceed 8% (1.7 million persons).
 •  Among people diagnosed with chronic 
HCV infection, 7% started treatment 
in 2015 (1.1 million persons). As of 
2015, a cumulative total of 5.5 million 
people with chronic HCV had ever 
received treatment, but the majority 
of these treatments were older, less 
eﬀ ective interferon-based regimens.
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A comprehensive response to hepatitis requires the 
implementation of effective, high-impact interventions 
along the full continuum of hepatitis services, including 
interventions for prevention, testing, treatment and 
chronic care (Fig. 3).
INTERVENTIONS ALONG THE CONTINUUM OF 
HEPATITIS SERVICES
WHO commissioned a mathematical model, which 
suggests that hepatitis B and C could be eliminated 
as a public health threat by 2030 if the response to 
viral hepatitis reaches the service coverage targets for 
fi ve core interventions (71, 72). These synergistic 
interventions for prevention, testing and treatment 
are at the core of an effective hepatitis response and 
are promoted through the GHSS on viral hepatitis 
(Table 5). This report provides the best estimate of 
service coverage for these fi ve interventions in 2015, 
the baseline, using standardized indicators.
FIVE CORE INTERVENTIONS SHOULD BE 
SCALED UP TO REACH ELIMINATION
Fig. 3. The continuum of viral hepatitis services and the retention cascade
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PREVENTION INDICATORS (INTERVENTIONS 
1–4, TABLE 5)
Within the public health system, interventions to prevent 
viral hepatitis are often led by different programmes 
(e.g. immunization, blood transfusion services and 
harm reduction). These programmes generate coverage 
estimates that can be used for monitoring and evaluation.
THE CASCADE OF CARE (INTERVENTION 5, 
TABLE 5)
At the population level, the “cascade of care” is 
a continuum of services that persons living with 
hepatitis should receive as they go through various stages, 
from diagnosis to treatment to chronic care and, for 
hepatitis C, to cure (see Fig. 3). The key indicators 
considered address diagnosis, treatment and viral 
suppression or the effectiveness of treatment.
•  Diagnosis. The indicator is the proportion of infected 
persons who are diagnosed. 
•  Treatment. The indicator is the subset of those 
diagnosed who are on treatment. Once diagnosed, 
infected persons are placed on long-term, usually 
lifelong, treatment (for hepatitis B) or short-term 
curative treatment (for hepatitis C).
•  Treatment effectiveness. This denotes the 
proportion of treated persons in whom the treatment 
is documented to be effective. For HBV, the indicator 
is the proportion of those on treatment who have viral 
suppression. For HCV, it is the proportion of those 
who have completed treatment and have a sustained 
virological response (viral load is measured 12–24 
weeks after completion of treatment). 
Table 5. Service coverage indicators for the core interventions of the Global Health 
Sector Strategy (GHSS) on viral hepatitis: 2015 baseline and targets
Targets
Interventions Indicator 2015 
baseline 
2020 2030
1 Hepatitis B vaccination HEPB3 coverage 84% 90% 90%
2 HBV PMTCTab HEP vaccine birth dose 
coverage
39% 50% 90%
3 Blood safety Donations screened with 
quality assurance
97% 95% 100%
Injection safety Proportion of unsafe 
injections 
5% 0% 0%
4 Harm reduction Syringes & needles 
distributed/PWID/year
27 200 300
5 Testing services % HBV-infected diagnosed 9% 30% 90%
% HCV-infected diagnosed 20% 30% 90%
Treatment % diagnosed with HBV on 
treatment
8%b –c 80%d
% diagnosed with HCV 
started on treatment
7%b – c 80%d 
a  Interventions to prevent the mother-to-child transmission of HBV
b  Less than 20% of persons living with HBV infection are eligible for treatment with antinucleos(t)ides available today.
c 5 million treated for HBV and 3 million treated for HCV (cumulative targets)
d Of those eligible for treatment
HEPB3: three doses of hepatitis B vaccine; PMTCT: prevention of mother-to-child transmission; 
PWID: person who injects drugs
Source: WHO, including commissioned work, United Nations, UNICEF and one published study (73)
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SERVICE COVERAGE OF CORE INTERVENTIONS
COVERAGE OF THIRD DOSE OF HEPATITIS B 
VACCINE HAS INCREASED, BUT NOT ENOUGH 
In 2015, the global coverage with the third dose of 
hepatitis B vaccine reached 84%, which is not far from 
90%, the 2020 target of the GHSS on viral hepatitis 
(Fig. 4). This high coverage explains the major reduction 
in the incidence of chronic HBV infection in children 
below the age of 5 years (see Chapter 2. Epidemiological 
update: increasing mortality calls for action). However, 
there are regional differences in coverage. The African, 
Eastern Mediterranean and European regions remain 
below the global average. Furthermore, national and 
subnational data often suggest that vaccination 
coverage varies between and within countries. 
Progress has been made since 1992, when the World 
Health Assembly formulated a resolution recommending 
the inclusion of hepatitis B vaccine in the EPI by 1997 
(WHA 45.17) (1).This resolution paved the way for 
nations to incorporate hepatitis B vaccine into their 
national immunization programmes. In 2015, 185 of 194 
WHO Member countries (95%) had included hepatitis 
B vaccine in the EPI. An additional nine countries used 
schedules that started later in life or that targeted high-
risk populations. Between 1990 and 2015, hepatitis B 
vaccine coverage in infants increased from 1% to 84% 
(WHO–UNICEF joint reporting form data), in part 
due to the support of the Global Alliance for Vaccines 
and Immunization (74) and to facilitated procurement 
through the revolving fund of the Region of the Americas.
PREVENTION OF MOTHER-TO-CHILD 
TRANSMISSION OF HBV REMAINS LOW IN 
FOUR REGIONS 
Following the progressive evolution in 2004 (75) and in 
2009 (1) of the global WHO recommendation to start 
hepatitis B immunization at birth, coverage of the birth 
dose increased, reaching 39% globally in 2015 (Fig. 5). 
In 2015, the birth dose of hepatitis B vaccine remained 
the cornerstone of prevention of transmission of HBV 
from mother to child. Ideally, the birth dose should be 
given within 24 hours of birth. However, the exact timing 
of administration of the birth dose is not clear as it is not 
always readily reported. While a birth dose can still be 
partially effective against mother-to-child transmission 
Fig. 4. Three-dose hepatitis B vaccine coverage, by WHO region, 2000–2015:
a major increase in coverage at the beginning of the 21st century 
Source: Joint UNICEF–WHO reporting form
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even if given more than 24 hours after birth, the effectiveness 
reduces with the passage of time (76). In 2015, coverage with 
the birth dose exceeded 70% only in the Region of the Americas 
and the Western Pacifi c Region. In the African Region, a region 
highly endemic for HBV infection, the 2015 coverage was 10%. 
In some countries of sub-Saharan Africa, coverage with three doses 
is high but that with the birth dose remains low (77). Prevention of 
mother-to-child transmission of HBV is particularly important in 
Asia, where the total number of women of childbearing age is large 
and many mothers have HBV infection with a high viral load. 
This high viral load is refl ected by a specifi c marker of HBV 
infection called hepatitis B e antigen (HBeAg).
In the absence of the universal birth dose or other effective 
interventions, the risk of transmission from the mother to the 
child remains a major source of chronic liver disease when infected 
children become adults (78). Efforts to deliver hepatitis B vaccine 
as soon as possible after birth, as well as increasing the number 
of births in health-care facilities and preventing mother-to-child 
transmission of other pathogens such as HIV and syphilis, should 
all be integrated. In the short term, administration of the birth 
dose needs to be scaled up worldwide, particularly in Africa. 
In the intermediate- and longer term, testing pregnant women 
for HBsAg and treating those HBV-infected before delivery will 
prevent transmission around birth (21). The concept of “triple 
elimination” of mother-to-child transmission of HIV, syphilis 
and HBV (79) could then be considered as an incremental 
intervention for countries that have achieved high coverage 
of the timely birth dose.
Fig. 5. Hepatitis B birth dose coverage, by WHO region, 2000–2015:
good progress in the Region of the Americas and Western Pacifi c Region
Source: Joint UNICEF–WHO reporting form
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09 – The fi rst dose of hepatitis B vaccine needs to be given 
as soon as possible after birth, ideally within 24 hours.
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UNSAFE HEALTH CARE, INCLUDING BLOOD AND 
INJECTION SAFETY
Unsafe health care is an effective mode of HBV and HCV 
transmission. With respect to HBV, universal vaccination 
now protects most children in whom new infections 
could be a source of chronic liver disease, but health-care-
associated infections remain a preventable source of acute 
hepatitis B in unvaccinated adults. With respect to HCV, 
health-care-associated infections add to the number of 
those chronically infected. Among all possible sources 
of health-care-associated transmission (e.g. dialysis, 
surgery, dental care), the GHSS includes blood and 
injection safety as a core intervention.
Unsafe blood transfusion is still a concern
Since 2000, WHO has identifi ed blood safety as a major 
public health priority (3). The proportion of donations 
from voluntary non-remunerated donors increased from 
54% in 2008 to 65% in 2013 (80). In 2013, among the 
137 countries that reported data on this indicator to the 
Global Database on Blood Safety, 97% were screening 
all blood donations using basic quality procedures, which 
included documented standard operating procedures and 
participation in an external quality assurance scheme. 
Among the low-income countries that reported data, 34% 
of blood donations were not screened using basic quality 
procedures (80). Further, eight countries reported not 
being able to test 100% of the blood collected for HBV, 
and 12 countries reported not being able to test 100% 
of the blood collected for HCV (80), often because of an 
irregular supply of test kits. In 2016, WHO published two 
guidance documents on haemovigilance (81) and external 
quality assessment programmes (82). Unsafe transfusion 
is not a major source of HCV or HBV transmission at a 
population level (66), because blood transfusions are an 
uncommon event in a person’s life compared with other 
unsafe health-care exposures, such as dental treatment 
or injections (83–85). However, unsafe blood transfusion 
is still a concern, especially in low- and middle-
income countries, where the prevalence of transfusion-
transmissible infections is high, and quality and coverage 
of blood screening are inadequate (86, 87).
Unsafe health-care injections remain a driver of 
the epidemic 
The Global Burden of Disease (GBD) 2000 study 
suggested that unsafe health-care injections were a major 
source of HCV infection. At that time, 30% of injections 
were given with injection equipment that had been reused 
without being sterilized. This accounted for about 30% 
of new HBV infections and 40% of new HCV infections 
(83). Since 2000, substantial efforts have been made by 
the international community, under the leadership of 
the Safe Injection Global Network, to reduce the risks 
associated with unsafe injections. In 2010, worldwide, 
5% of health-care injections were given with unsterilized, 
reused injection devices (Fig. 6) (73), which caused 
315 000 and 1 679 000 new HCV and HBV infections 
worldwide, respectively (40). Progress in reducing unsafe 
health-care-associated injections was uneven across all 
WHO regions. According to 2010 data, health-care 
injections remained particularly unsafe in some countries 
of the Eastern Mediterranean Region, with 14% reuse 
still detected and a large number of unsafe injections 
per capita. The South-East Asia Region remains an area 
of concern with an average 5% reuse. In addition, the 
excessive use of injections to administer medications is a 
matter of concern (40, 88). Coupled with poor injection 
practices, injection overuse accelerates transmission. 
This persisting driver of transmission needs to be 
addressed through safer health care, introduction 
of reuse-prevention devices (89) and a reduction in 
unnecessary health-care injections, particularly in the 
Eastern Mediterranean and South-East Asia regions. 
More recent data are also needed to monitor the evolution 
of injection safety since 2010.
11 – Prevention of injection-associated infections is about 
reducing injection overuse and making injections safe.
10 – Blood transfusion safety has improved since it was made a priority in 2000.
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HARM REDUCTION INTERVENTIONS AND SERVICES
WHO, UNODC, UNAIDS and the World Bank 
estimate (90) that in 2015, globally, there were 11.8 
million persons who inject drugs (0.25% of the world 
population)(91). Harm reduction includes, but is not 
limited to, distribution of sterile needle and syringes to 
people who inject drugs (92). Implementation of harm 
reduction interventions for people who inject drugs 
is inadequate. The critical indicator of the number of 
syringes distributed annually per person who injects 
drugs falls short (27 syringes/person who injects drugs/
year) of the 2020 target of 200 syringes/year/person who 
injects drugs. These data are from a review published in 
2010 (93), which is currently being updated. Ideally, the 
value should be at the 2030 target, which is 300 syringes/
year/person who injects drugs (Table 6). However, only 
26% of countries have the information that would allow 
them to monitor the situation. The substantial size of 
the population of people who inject drugs and their poor 
access to harm reduction services explains why injection 
drug use remains a key factor of HCV transmission in 
many countries. Overall, there is a need to scale up harm 
reduction services and implement policies that address 
stigma/discrimination (94).
Fig. 6. Proportion of health-care injections given with equipment reused without sterilization, by WHO region, 2010: 
problems persist specifi cally in the Eastern Mediterranean and South-East Asia regions 
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Source: Pepin at al. (40)
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 WHO region Size of the population injecting drugs Proportion 
of countries 
with needle 
and syringe 
programmes 
(%)b
Needle and syringe 
distributionc (93)
Numbera
(millions)
Prevalence 
(%) in the 
population 
15–64 
years
Proportion 
of 
countries 
reporting 
data on 
PWID (%)
% of 
countries 
with datad
Median 
# of 
syringes/
PWID/
yeare
African Region 0.52 0.1 30 11 2 6
Region of the Americas 2.75 0.42 34 26 9 22
Eastern Mediterranean Region 0.92 0.23 43 38 14 25
European Region 3.97 0.66 92 91 58 59
South-East Asia Region 0.56 0.04 82 55 55 29
Western Pacifi c Region 3.03 0.23 33 33 26 57
World 11.75f 0.25 53 36 26 27
Table 6. Size of the population injecting drugs and harm reduction indicators, by region:
major gaps towards targets of the global strategy
a  UNODC. World Drug Report 2017 (forthcoming, to be released on 22 June 2017). (For countries not reporting data on 
people who inject drugs [PWID], the regional prevalence was used to extrapolate the PWID population size.)
b   This refers to the proportion of countries in the region with at least one operational needle and syringe programme 
(NSP) (Reference: The global state of harm reduction 2016. Harm Reduction International. (https://www.hri.global/
contents/1739).
c   The data on needle–syringe distribution is poor and not recent – this review is currently being updated and will be 
published towards the end of 2017.
d   Countries reporting NSP and reporting data on the number of needles–syringes distributed 
e   The median among those countries reporting NSPs and data on number of needles–syringes distributed
f   This total excludes countries and territories not classifi ed as full WHO Member States.
TESTING AND TREATMENT
Various approaches can be used in countries to test 
persons for infection with HBV or HCV. These range 
from testing in highly affected populations to testing 
in the general population, sometimes with a focus on 
persons in older age groups (a strategy referred to as 
“birth cohort” approach). In 2016, WHO published a 
policy brief on guidelines for testing persons for HBV 
and HCV infection (62). This was followed by publication 
of the full guidelines in early 2017 (95). These guidelines 
describe how to test, who to test and how to make sure 
that persons tested are referred to care. Interventions 
that should be considered to promote uptake of hepatitis 
testing and linkage to care include peer and lay health 
worker support in community-based settings, reminders 
to providers and provision of hepatitis testing as part of 
integrated services within mental health/substance use 
services (96).
Cascade of care for HBV
Since 1985, treatment for HBV infection became 
possible and progressively improved, fi rst with interferon and, 
more recently, with the advent of newer medicines. Various 
antiviral agents are registered for the treatment of HBV in 
high-income countries. In 2015 (22), WHO formulated a 
recommendation to include nucleos(t)ide analogues with a 
high barrier to resistance (i.e. tenofovir, entecavir). These are 
easier to administer (one pill a day), more effective, have less 
side-effects and induce less resistance. However, they seldom 
result in cure. Therefore, at present, long-term (potentially 
lifelong) therapy is required for the majority of patients. 
Following the formulation of the guidelines, WHO worked 
to disseminate these guidelines through regional workshops 
and translations.
In 2015, of the 257 million persons living with HBV 
infection, 9% (22 million) knew their diagnosis (Fig. 7). 
Of those diagnosed, the global treatment coverage was 
only 8% (1.7 million) in 2015. However, among the 
22 million diagnosed, the proportion of persons eligible for 
treatment is unknown. Once on treatment, adherence to 
treatment infl uences the proportion of patients with viral 
suppression (97).
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Fig. 7. Cascade of care for HBV infection, by WHO region, 2015:
eﬀ ective treatment is underused in most regions 
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BOX 2. PROLIFICA: A PILOT APPROACH TO TESTING AND TREATMENT FOR HBV 
INFECTION IN THE GAMBIA
The Gambia (West Africa) introduced hepatitis B vaccination in 1986, earlier than in 
many other countries. Despite this, chronic HBV infection remains common in the country: 
9% of the adult general population is infected. The PROLIFICA (Prevention of Liver Fibrosis 
and Cancer in Africa) research study provided data on the feasibility and cost–eﬀ ectiveness 
of population-level screening and treatment for HBV infection. As part of the PROLIFICA 
project, people have been tested and referred to care using two approaches (23). First, during 
community-based testing activities, 69% of 8170 individuals who were approached accepted 
to be tested. Of those tested, 8.8% were infected with HBV. Of those infected, 81% were linked 
to care. Second, persons coming to donate blood were tested. Of the 6832 donors, 81% were 
tested, and 13% were infected with HBV. Forty-two per cent of infected persons were linked 
to care. Only less than 10% needed treatment (98). After a year of treatment, 91.5% had viral 
suppression. Overall, in the Gambia, community screening was cost eﬀ ective (99). The project 
can now be considered for scaling up, although further negotiations are needed on the pricing 
of diagnostics and medicines, as well as improvements in the supply chain.
Source: WHO estimates, conducted by the Center for Disease Analysis. See Annex 2.
a     As the proportion of persons eligible for treatment among those diagnosed is unknown, the treatment gap 
cannot be calculated. 
12 – Diagnosis of hepatitis can be made with oral fl uids, 
without a blood test.
13 – Most medicines for HBV or HCV infection can be 
administered orally.
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Cascade of care for HCV
In the decades following the discovery of HCV in 1989, 
the treatment of persons with HCV infection became 
possible. The fi rst HCV treatments were based on various 
types of interferon. The addition of ribavirin, an antiviral 
drug, increased cure rates. However, treatments based on 
interferon/ribavirin were poorly tolerated, associated with 
severe adverse effects, and resulted in cure rates of between 
40% and 65%, depending on various factors. A dramatic 
improvement in HCV therapy followed the introduction 
of oral medicines that directly inhibited the replication 
cycle of HCV, called direct-acting antivirals (DAAs). 
In 2013, sofosbuvir was registered in the United States 
of America. DAAs are usually used in combination. 
As of October 2015, eight separate DAAs had been 
approved for the treatment of persons with HCV 
infection. WHO released its fi rst guidelines on HCV 
treatment in 2014 (100), and updated these in 2016 (54).
Access to HCV treatment is improving, but remains 
limited. In 2015, of the 71 million persons living with 
HCV infection globally, 20% (14 million) knew their 
diagnosis. The Region of the Americas had the highest 
proportion of those diagnosed (36%), while the African 
Region had the lowest (6%, Fig. 8). Worldwide, 7% of 
those diagnosed (1.1 million) were started on treatment 
in 2015. The Eastern Mediterranean Region accounted 
for the largest proportion of those started on treatment 
(12%), boosted by the large-scale elimination plans in 
Egypt (101). Of those started on treatment in 2015, about 
half received DAAs. Given that more people were initiated 
on treatment the following year, in 2016, the WHO 
global report on access to hepatitis C treatment estimated 
that about 1 million persons had accessed DAAs in 
selected countries (102). However, there is wide variation 
in terms of access to DAAs from country to country. 
For example, in 2015, the HCV elimination programme 
in Egypt was based on the use of DAAs.
Globally, over the years, the cumulative number of 
those placed on treatment reached 5.4 million persons in 
2015. Most of the patients treated before 2015 received 
older treatments, primarily interferon-based therapies. 
Of the persons that completed treatment in 2015, it is 
projected that 80% (843 000) overall achieved a sustained 
virological response (SVR). The projected proportion 
of those with an SVR was highest in the Region of 
the Americas (88%) and lowest in the Western Pacifi c 
Region (63%). These regional differences in SVR refl ect 
differences in access to newer DAAs.
Fig. 8. Cascade of care for HCV infection, by WHO region, 2015
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LONG-TERM FOLLOW UP AND CHRONIC CARE
Patients with chronic hepatitis infection who do not initiate antiviral treatment 
or for whom treatment is unsuccessful, may require ongoing care. This care will 
include services such as monitoring for hepatocellular carcinoma, management of 
symptoms and palliative care. Monitoring the cascade of care beyond treatment 
will ensure that services remain comprehensive and patient-centred.
WHAT CAN BE DONE TO REACH SUFFICIENT 
COVERAGE LEVELS FOR ELIMINATION?
WHICH DATA SYSTEMS ARE NEEDED FOR 
MONITORING AND EVALUATION OF A 
NATIONAL RESPONSE?
•  Reaching those who have not yet been reached with 
hepatitis B immunization, particularly in the African, 
European and Eastern Mediterranean regions
•  Expanding access to the birth dose of hepatitis B 
vaccine so that it becomes a standard of care beyond 
the Region of the Americas and Western Pacifi c Region 
•  Provision of safe blood and safe injections to ensure 
that the viruses causing hepatitis are not spread 
through unsafe health care 
•  UNICEF/WHO reporting of immunization coverage
• Indicators of harm reduction
•  Proportion of injections given with devices reused 
without sterilization (from health-facility surveys)
•  Data on the cascade of care for HBV and HCV, 
from patients’ databases. 
•  Scaling up harm reduction services (particularly 
access to sterile injecting equipment and opioid 
substitution therapy for opioid users), with full 
documentation and supportive policies 
•  Provision of testing services to identify those 
who do not know their infection status
•  Ensuring secure access to safe, effective 
treatment for those identifi ed with infection
14 – What gets measured gets 
done: register of the timing of the 
hepatitis B birth dose, China.
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DELIVERING FOR EQUITY: 
NEED FOR A PUBLIC 
HEALTH APPROACH
15 – People who inject drugs continue 
to face stigma, discrimination and 
limited access to appropriate services. 
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•  Within countries, some population 
groups diﬀ er in terms of incidence or 
prevalence of HBV or HCV infection. 
Vulnerability and needs vary also. 
Groups in need of specifi c prevention, 
testing, care and treatment approaches 
include health-care workers, persons 
who inject drugs, indigenous peoples 
and minorities, prisoners, migrants, 
men who have sex with men, persons 
coinfected with HIV and hepatitis and 
blood donors. 
•  The hepatitis C epidemic and injection 
drug use are two public health 
issues interconnected at the levels 
of transmission, management and 
mortality. Worldwide, 11.8 million 
persons who inject drugs are in need 
of prevention and treatment services. 
Injection drug use accounts for 1% of 
new HBV infections and 23% of new 
HCV infections. Among persons with 
chronic infection, 0.5% of those living 
with HBV and 8% of those living with 
HCV currently inject drugs. 
KEY FINDINGS
•  Low- and middle-income countries 
account for the largest proportion 
of persons living with HBV (96%) and 
HCV (72%), yet access to testing and 
treatment is more limited in these 
countries. 
•  To increase access and reduce 
health inequities, delivery of hepatitis 
and harm reduction services can 
be tailored to diﬀ erent populations 
and settings through integration, 
decentralization and task-shifting.
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VIRAL HEPATITIS DISPROPORTIONALLY 
AFFECTS CERTAIN POPULATION GROUPS
A number of population groups have specifi c profi les 
in terms of incidence and prevalence, which differ for 
HBV and HCV. Vulnerabilities and needs also vary 
across groups. Disaggregated data should be used at 
country level to describe these populations in terms 
of incidence, prevalence, vulnerability and needs. 
This information makes it possible to focus resources 
where they are needed the most, and adapt services to 
achieve the highest impact. Groups with high incidence 
especially need intensifi ed prevention services. 
Groups with high prevalence need improved testing 
and treatment services. Other individuals, communities 
and populations more vulnerable to hepatitis because of 
their poor access to appropriate health care or because 
they are marginalized or stigmatized need access to 
client-friendly care, without discrimination.
Health-care workers: protecting those at the 
frontline of the response
Health-care workers are at higher risk of infection 
with HBV and HCV because of exposure to blood and 
body fl uids, usually through needle-stick injuries (103). 
A safe working environment for health-care workers 
should include the offer of HBV immunization (104). 
With respect to HBV, health-care workers often have 
a higher prevalence of serological evidence of past or 
present infection, which refl ects a higher cumulative risk 
of infection during their lifetime (105). With respect 
to HCV, the higher risk of infection does translate into 
a higher prevalence (106), which could be taken into 
account while defi ning population groups that should 
be tested for HCV infection.
Persons who inject drugs: comprehensive care 
needed for prevention and treatment 
Injection drug use affects the three components of the 
HBV and HCV epidemics in different ways (Table 7).
1.  New infections. Injection drug use accounts for 
1% of new HBV infections and 23% of new HCV 
infections. In settings with intermediate and high HBV 
endemicity, by the time potential drug injectors reach 
adulthood, most are chronically infected with HBV 
or were infected in the past (107).
2.  Chronic infections. A lower proportion of those 
with HBV infection (0.5%) are current or recent 
injection drug users than those with HCV infection 
(8%). Unlike for HCV, most adults who acquire 
HBV infection through injection drug use are likely 
to clear the infection because of their age. Testing 
and treatment services for those with chronic HCV 
infection need to link with services for the management 
of drug dependence, such as opioid substitution 
therapy, to improve treatment adherence and outcomes. 
3.  Mortality. Of all the deaths from cirrhosis and 
hepatocellular carcinoma, 0.9% of deaths due to HBV 
infection and 31% of deaths due to HCV infection 
are attributable to a lifetime history of injection drug 
use. Overall, the high incidence of HCV infection 
and the high probability of chronic HCV infection 
in persons who inject drugs mean that injection drug 
use explains a much larger share of viral hepatitis 
mortality than HBV infection. Therefore, reaching the 
mortality target of HCV elimination will be possible 
only if injection drug use is addressed from a public 
health perspective, within a broad policy context that 
includes prevention of initiation of injection drug 
use, prevention of stigma and discrimination, and 
the provision of a full spectrum of harm reduction 
interventions (94).
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Table 7. Role of injection drug use in acquisition of new infections, chronic infections and deaths from HBV and HCV, 2015
New infections Chronic infections Deaths from cirrhosis and 
hepatocellular carcinoma
Total Attributable to 
current injection 
drug use
Total Among persons who 
currently inject (or 
recently injected) drugs
Total Attributable to 
lifetime injection 
drug use
# 
(million)
# 
(million)
% # 
(million)
# (million) % # (000s) # (000s) %
HBV N/A N/A 1.2 257 1.3 0.5 890 8.1 0.9
HCV 1.7 0.39 23.0 71 5.6 8 400 126.0 31.5
Source: Calculation based on published data (107, 108) (see Annex 2 at the end of this report). 
In 2009, WHO, the United Nations Offi ce on Drugs 
and Crime (UNODC) and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) defi ned a package 
of nine interventions for people who inject drugs, which 
includes access to sterile injecting equipment, opioid 
substitution therapy for opioid users and other drug 
dependence treatment, and risk reduction information 
and education (109). Opioid substitution therapy reduces 
the frequency of injecting behaviour, thereby reducing 
the transmission of bloodborne pathogens among people 
who use opioids. In addition, in countries with low 
HAV endemicity, people who inject drugs should also 
receive hepatitis A vaccine (110). A study estimated that 
the investment in harm reduction in Australia will be 
entirely recovered in health-care cost savings by 2032 
(111). Mathematical modelling indicates that high service 
coverage for people who inject drugs will be essential for 
eliminating HCV (112). However, in many countries, 
political resistance to harm reduction services, stigma, 
discrimination and criminalization reduce accessibility 
and coverage.
Indigenous peoples and minorities need adapted 
approaches 
Indigenous populations and minorities in many parts 
of the world have a high prevalence of HBV infection, 
including peoples of the Indian Ocean (in the Andaman 
and Nicobar Islands of India (113)), the Arctic (114, 115), 
the Americas (116), New Zealand (Maori), Australia 
(117) (Aboriginal and Torres Strait Islander peoples) 
and in Europe (the Roma) (118–120). Some indigenous 
communities also have a high prevalence of HCV 
infection (121, 122). These populations are often excluded 
from or have poor access to health-care services, because 
they live in remote communities, are discriminated against 
or because the services are not sensitive to their cultural 
differences. National viral hepatitis plans need to include 
specifi c strategies to facilitate access to prevention, care 
and treatment for indigenous populations and minorities. 
Box 3 provides an example from the Amazon region of the 
Americas (123).
BOX 3. HEPATITIS B AND D AMONG INDIGENOUS PEOPLES OF THE 
AMAZON BASIN 
The Amazon Basin is home to some 385 indigenous groups, totalling approximately 33 
million people in nine countries of the Americas (124). These groups are marginalized and 
live under diﬃ  cult social and economic conditions. Endemicity of HBV infection in the 
Amazon Basin is intermediate to high. Prevalence ranges from 1% to over 14% among 
diﬀ erent indigenous populations and age groups (123). Wide-scale implementation of 
universal infant hepatitis B vaccination helped to lower the prevalence of HBV infection 
in several countries of the Amazon Basin (125). Studies have reported reductions in 
prevalence in indigenous peoples over the past decade. Timely coverage with birth 
dose vaccination among indigenous peoples varies within countries and communities. 
Indigenous peoples also have a high endemicity of HBV infection and HDV superinfection 
(123). HDV prevalence among HBV-infected persons ranges from 7% to 42% (126, 127). 
Family outbreaks of fulminant hepatitis have been reported in small villages of the 
western Brazilian Amazon region (127), in other areas of Brazil and Ecuador (128).
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Prisoners: higher prevalence in a vulnerable 
population 
In most countries, the prevalence of HBV and HCV 
infection among prisoners is higher than the prevalence 
in the general population (129). The overrepresentation of 
people born in countries with higher endemicity (HBV), 
other ethnic minorities (HBV) and the higher frequency 
of injection drug use (HCV) among prisoners may 
explain this higher prevalence (130, 131). Prisoners are a 
vulnerable population in need of comprehensive hepatitis 
prevention, testing and treatment services (132, 133).
Migrants: higher prevalence among persons who 
struggle to access health care
Persons may migrate from countries with a high 
prevalence of HBV or HCV infection to countries with a 
low prevalence. In the European Union, migrants account 
for an estimated 25% of persons living with HBV and 
14% of persons living with HCV. This is higher than the 
proportion of migrants in the total population, which 
is 5% for migrants from countries with intermediate 
and high HBV endemicity, and 8% for migrants from 
countries with high HCV endemicity. Despite a high 
prevalence of chronic infection among migrants, the risk 
of transmission to the population in their countries of 
arrival is likely to be low since HBV and HCV are not 
transmitted through casual contact (134). However, given 
the diffi culties migrants face in accessing health care, 
hepatitis-specifi c prevention and care services should 
focus on migrant populations, and provide accessible 
opportunities for timely testing and treatment.
Blood donors: missed opportunities to link donors 
diagnosed with hepatitis to care
In voluntary, non-remunerated blood donors recruited 
with effective education and selection programmes, 
the prevalence and incidence of HBV and HCV infection 
should be lower than in the general population. 
Despite a lower prevalence and incidence, screening of 
blood donors may lead to tests that are positive for HBV 
or HCV infection. Globally, an estimated 1.6 million 
units are discarded annually due to the presence of 
markers for transfusion-transmitted infections, including 
HIV, HBV, HCV and syphilis (80). However, donors 
with reactive tests are not always managed appropriately. 
Following confi rmatory tests, they should either be 
returned to the pool of blood donors (if not infected) 
or be further assessed for treatment (if infected) (135).
16 – Viral hepatitis testing in the Amazon, Brazil.
SPECIFIC POPULATION 
GROUPS DIFFER IN TERMS 
OF INCIDENCE, PREVALENCE, 
VULNERABILITY AND NEEDS. 
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Men who have sex with men: higher risk of 
HAV and HBV infection, and recent reports of 
HCV infections
Men who have sex with men are at higher risk of 
HAV and HBV infection (136). In addition, an increased 
incidence of HCV infection has been reported among 
those who are HIV-infected (50). Where feasible, 
men who have sex with men should be considered for 
hepatitis B catch-up vaccination (1). In countries with 
low HAV endemicity, they should also receive hepatitis A 
vaccination (110). Since HBV infection acquired during 
adulthood uncommonly leads to chronic infection, the 
prevalence of chronic HBV infection among men who 
have sex with men is unlikely to differ from the prevalence 
in the general population. With respect to HCV infection, 
HIV-positive men who have sex with men would benefi t 
from testing for HCV infection, and more extensive 
risk behaviour counselling and targeted HCV 
prevention services, as well as access to treatment.
Coinfection
Persons with HIV–HBV or HIV–HCV coinfection are 
at risk for accelerated disease progression, stigma and, 
in some instances, compromised access to health 
services. They may also belong to population groups 
that are stigmatized because of injection drug use or 
sexual behaviours. 
MEASURING HEALTH INEQUALITIES AMONG 
VULNERABLE POPULATIONS 
Monitoring the indicators of the cascade of care for 
population subgroups ensures that the response addresses 
all those in need. Information on access to hepatitis care 
disaggregated by population subgroups is limited and 
mostly available from high-income countries (although 
it would be relevant everywhere). Investigators have 
examined the cascade of care for HBV and that for 
HCV from two different approaches. Cross-sectional 
methods look at the overall population (137) and examine 
whether everyone progresses in the same way along the 
cascade of care. They can provide information on specifi c 
subgroups if data are disaggregated according to specifi c 
characteristics (e.g. injection drug use (138)), health 
insurance coverage or minority group status (139)). 
Cohort methods tend to be used by those who provide 
services to these specifi c populations. Therefore, persons 
included in cohort cascades are only those who are able 
to access these services, including transition clinics for 
individuals recently released from incarceration (140), 
community-based services for persons who inject 
drugs (141) and dedicated health services for 
indigenous peoples (142).
17 – Unique identifi ers can protect confi dentiality while 
facilitating data management.
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A PUBLIC HEALTH APPROACH WILL INCREASE 
ACCESS AND REDUCE HEALTH INEQUITIES 
A public health approach balances the best possible 
standards of care with the feasibility of implementation. 
This approach uses evidence-based, simplifi ed, 
standardized, effective, affordable methods that can 
be scaled up, including in resource-limited settings. 
Given the limited resources in low- and middle-
income countries, elimination of viral hepatitis will 
be possible only by following a public health approach 
that strengthens the health system and not through 
establishing new disease-specifi c programmes. 
This approach alone can go beyond individual 
benefi ts and reach the largest number of persons
possible to reduce inequities. The hallmarks of 
robust and fl exible health systems are: 
•  a strong health information system; 
• effi cient service delivery models; 
•  adequate numbers of an appropriately trained 
workforce that is well distributed and has the 
appropriate skills mix (Box 4);
•  reliable and uninterrupted access to essential 
medical products and technologies; 
• adequate health fi nancing; 
• strong leadership and governance.
Viral hepatitis affects persons in all countries and from 
all income levels. However, low- and middle-income 
countries account for the highest burden and face the 
greatest challenges in scaling up testing and treatment 
for affected populations.
LOW-INCOME COUNTRIES HAVE A HIGHER 
BURDEN OF HBV INFECTION, BUT LIMITED 
AVAILABILITY OF TESTING AND TREATMENTa 
The prevalence and incidence of HBV infection are 7.4 
and 9.2 times higher, respectively, in low-income countries 
than in high-income countries. However, the proportion 
of diagnosed individuals decreases from 18% in high-
income countries to 0.8% in low-income countries. 
Among those diagnosed, the proportion accessing 
treatment also decreases from 14% in high-income 
countries to 9% in low-income countries.
LOW- AND MIDDLE-INCOME COUNTRIES 
HAVE LIMITED AVAILABILITY OF TESTING AND 
TREATMENT FOR HCV INFECTIONb
High-, middle- and low-income countries do not differ 
in terms of incidence or prevalence of HCV infection. 
However, most persons living with HCV infection 
live in middle-income countries because most of the 
world’s population lives in middle-income countries. 
The proportion of persons infected with HCV who are 
diagnosed is higher (46%) in high-income countries than 
in low- and middle-income countries (6%). Annual rates 
of treatment initiation are also higher in high-income 
countries (8%) than in middle-income and low-income 
countries (2%). In 2015, access to DAAs was diffi cult in 
low- and middle-income countries; therefore, projected 
cure rates were lower in low- and middle-income countries 
than in high-income countries. The access patterns are, 
however, changing rapidly with the decreasing prices of 
generic formulations.
VIRAL HEPATITIS DISPROPORTIONALLY 
AFFECTS PEOPLE LIVING IN LOW- AND 
MIDDLE-INCOME COUNTRIES
a  WHO estimates conducted in collaboration with LSHTM, data not shown
b  WHO estimates conducted in collaboration with Center for Disease Analysis, data not shown
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Interventions for addressing hepatitis are most effective when they are tailored to 
specifi c populations and settings, and implemented within social, legal and policy 
frameworks that enable all people to access and use services.
BOX 4. TASK-SHIFTING TO DECENTRALIZE CARE CAN INCREASE EQUITY, 
REDUCE COSTS AND ENSURE THE QUALITY OF HEPATITIS SERVICES IN 
SOME SETTINGS 
Telemedicine distance-learning systems can expand the capacity to treat chronic 
hepatitis (143). Models have been proposed based on four pillars: (i) use of technology to 
leverage scarce resources; (ii) sharing best practices to reduce disparities; (iii) mastering 
complexity through case-based learning; and (iv) monitoring outcomes. Telemedicine 
distance-learning systems build capacity among physicians, physician assistants, nurse 
practitioners, nurses, community health workers, and other health-care professionals so 
that patients are treated by local providers they already know and trust. Videoconferences 
can be accessible through most platforms, including cellular phones. Capacity-building 
sessions can include a brief lecture, guided practice and mentoring through case-based 
learning. In addition to addressing viral hepatitis, they can also touch on substance use 
disorders, which can help in integrating services for patients (144). Telemedicine distance-
learning systems have been used in more than 110 academic medical centres in over 20 
countries, including Egypt, India, Georgia, Kazakhstan, Kenya, Namibia, Tanzania, Ukraine 
and Viet Nam. Evaluation has indicated that the outcome of patients treated by providers 
trained using these methods is no diﬀ erent from the outcome of patients treated by 
specialists (145). Further, such task-shifting reduces disparities in treatment practices, 
increases access, including in prisons and rural areas, improves quality and reduces costs.
HOW CAN A PUBLIC HEALTH APPROACH 
REDUCE INEQUITIES?
There are differences between and within countries in terms of incidence, prevalence, 
vulnerable populations and capacity to respond. The highest burden from viral hepatitis 
is found in low- and middle-income countries. Eliminating hepatitis will be possible 
if these countries follow a public health approach that strengthens health systems and 
reduces inequities. Progress in reducing inequities can be measured by disaggregating 
incidence, prevalence and service coverage data at country level for specifi c populations. 
Hepatitis services should be prioritized for those populations with a higher incidence, 
prevalence and/or increased vulnerability, and adapted to specifi c needs.
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FINANCING FOR 
SUSTAINABILITY: MAKING 
ELIMINATION AFFORDABLE
18 – NOhep: a global movement 
to call for action.
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•  There is currently limited funding 
available at the international level to 
support national hepatitis elimination 
plans. Therefore, countries will need 
to fi nance most of their response 
through domestic sources. Economic 
analyses can be used to make an 
investment case.
•  The prices of medicines and diagnostics 
are the key drivers that infl uence the 
economic analysis of viral hepatitis 
elimination plans.
•  WHO-recommended treatment for 
HBV infection is available as generics 
in most low- and middle-income 
countries and costs as little as US$ 48 
for a year of treatment. The prices of 
WHO-recommended DAAs for HCV 
vary substantially (US$ 200–45 000 
for a curative course), but prices have 
been falling rapidly, and most low- and 
middle-income countries should be 
able to procure generic medicines at 
aﬀ ordable prices.
KEY FINDINGS
•  The cost of prequalifi ed serological 
tests used to identify those with HBV 
and HCV infection varies from US$ 0.5 
to US$ 3. Nucleic acid tests that are 
required to make treatment decisions 
are more expensive (US$ 25–200), 
and need to be made available at 
lower cost.
•  There are opportunities for the 
public sector to procure medicines 
and diagnostics on the international 
market at low cost. When this is the 
case, treatment can be cost eﬀ ective, 
or even cost-saving, from a health-
care perspective.
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New treatments for HBV and HCV infection offer 
new opportunities. However, the costing, budgeting 
and fi nancing of viral hepatitis services have changed. 
New medicines and diagnostics bring additional costs,
but they can lead also to savings, improved health 
outcomes and increased productivity.
In 2017, despite the large burden of disease, investments 
in hepatitis remain limited at the national and 
international levels when compared with some 
other major infectious diseases.
FUNDED NATIONAL PLANS: MOSTLY IN HIGH-
INCOME COUNTRIES, BUT ALSO IN A FEW LOW- 
AND MIDDLE-INCOME COUNTRIES 
At the national level, apart from high-income countries 
that have formulated national elimination plans, 
such as France, Australia and the United States, 
the number of low- and middle-income countries that 
have currently secured funds for a scaled-up response is 
limited. However, a number of high-burden countries 
have elaborated fi nancing plans that include testing and 
treatment, including Brazil, Egypt, Georgia, Mongolia 
and Myanmar. In the absence of fi nancing plans in 
many countries, patients organize themselves to procure 
medicines through “buyers’ clubs” or, those who can 
afford travel, seek treatment in countries that offer 
medicines at low prices. These initiatives may provide 
access to treatment for individuals but do not secure 
access to quality medicines for all those who need them.
Funding an increase in HCV treatment uptake 
in Australia
In 2016, an economic analysis in Australia used a 
mathematical model to study which treatment strategies 
would most effectively and effi ciently eliminate hepatitis 
C in the country, based on the WHO strategy’s targets 
(112). On the basis of the results of this analysis, in March 
2016, the Australian Pharmaceutical Benefi ts scheme 
listed a number of DAAs for the treatment of hepatitis 
C for which it covers the majority of the drug costs. As a 
result, in 2016, from March to September, an estimated 
25 900 persons were started on treatment, representing 
11% of those living with HCV infection (146). 
CURRENT INVESTMENTS IN HEPATITIS 
REMAIN LIMITED
THE ECONOMICS OF ELIMINATION OF 
VIRAL HEPATITIS ARE CHANGING
Perspectives for universal hepatitis C treatment 
in France
France has a national viral hepatitis plan that addresses 
HBV and HCV. The plan includes reimbursement of 
the cost of DAAs against HCV by the national health 
insurance scheme (147), and specifi c approaches to 
reach injecting drug users, persons in prisons, migrants 
and persons coinfected with HIV. Treatment of all 
persons infected with HCV, irrespective of fi brosis, 
is also considered as part of operational research. 
WHO-recommended medicines for treatment 
of hepatitis B included under health insurance 
in China
More than 90 million persons are chronically infected 
with HBV in China. Ninety-eight per cent of the 
population is covered by basic health insurance. 
In February 2017, entecavir and tenofovir, the WHO-
recommended medicines for the treatment of hepatitis B, 
were included in the updated national list of reimbursable 
medicines. The decision signifi es critical progress 
towards universal coverage for hepatitis B treatment 
in the country. However, implementation is complex. 
Provinces and health facilities have the fl exibility to make 
further decisions and the health insurance systems are 
undergoing reform. In 2018, when tenofovir comes off-
patent in China, the costs of medicines are expected to 
drop, which should further increase treatment access.
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INTERNATIONAL RESPONSE: LIMITED 
FUNDS AVAILABLE
The Global Fund to Fight AIDS, Tuberculosis and 
Malaria does not currently provide funding for the viral 
hepatitis response, other than for persons who also have 
HIV infection. 
UNITAID was one of the fi rst donors in the fi eld of 
HCV to accelerate access to innovative new health 
products, which is at the heart of its role. UNITAID 
supports a number of partners with a mandate to work 
on HIV–HCV coinfection. These include Médecins 
Sans Frontières, with a project to treat HCV infection in 
HIV-infected people in resource-limited settings using 
simplifi ed models of care, Coalition Plus to increase 
general awareness about hepatitis, and the Foundation for 
Innovative New Diagnostics (FIND), to develop easy-to-
use diagnostics and facilitate diagnosis in health facilities 
with limited laboratory infrastructure. Together, these 
projects will help jump-start the cycle of demand and 
supply (148).
In June 2016, a collaborative effort by the United States 
Centers for Disease Control and Prevention, WHO and 
the ZeShan Foundation led to the fi rst International 
Roundtable Summit on Funding for Elimination of 
Viral Hepatitis (149).
MAKING THE CASE TO INVEST IN TESTING 
AND TREATMENT
Economic analyses guide decision-making and 
determine acceptable pricing levels
Economic analyses have helped to secure additional 
investment for the elimination of viral hepatitis. Given the 
large share of commodities in the costing of the response 
to viral hepatitis, economic analyses can also estimate 
the price at which these commodities can be affordable 
from a health-care perspective. WHO has proposed key 
principles to be taken into account for cost–effectiveness 
analyses (150). The results of such cost–effectiveness 
analyses can be considered along with other criteria used 
to allocate resources within the health sector (151) to set 
priorities within the limited budget envelope 
of the health system. 
Economic analyses make the case for care 
and treatment 
In Egypt, the prevalence of hepatitis C infection is 
very high and direct health-care costs for hepatitis 
already consume 4% of the total health expenditure. 
As indirect costs represent twice the direct costs, the total 
costs amount to 1.4% of the gross national product. 
An economic analysis, however, indicated that treating 
328 000 persons with hepatitis C infection annually 
by 2018 with direct-acting antivirals could reduce the 
prevalence of infection by 94% and liver-related deaths 
by 75% by 2030 (101). Treatment is highly cost effective 
from health-care perspective, and when indirect costs are 
taken into account, the intervention is cost-saving. Since 
2015, treatment has been based on direct-acting antivirals 
and, as of March 2017, at least a million persons have 
already received treatment in the public sector (with more 
being treated in the private sector). Since the waiting lists 
for treatment have been cleared, Egypt is now actively 
testing in the general population as the next step 
towards elimination.
In the Gambia, a study examined the cost–effectiveness of 
a community-based programme for testing and treatment 
for HBV infection (99). The results of the analysis suggest 
that this intervention is cost effective. A reduction in the 
prices of key commodities and stronger integration within 
the health-care services could make the intervention 
highly cost effective or cost-saving.
In India, where the cost of a curative course of HCV 
treatment was US$ 200 in 2016, a study examined 
the cost–effectiveness of hepatitis C treatment.
(Aggarwal R, Chen Q, Goel A, Seguy N, Pendse R,
Ayer T, Chhatwal J. Cost-effectiveness of hepatitis 
C treatment using generic DAAs available in India, 
Manuscript submitted for publication). The results of 
the analysis suggest that this intervention is cost-saving. 
Treatment is cost effective after 2 years and the 
threshold for cost-saving is reached after 10 years.
In China, the annual treatment for hepatitis B with 
branded tenofovir costs US$ 2920 per year when 
purchased by patients, but only US$ 360 when purchased 
for HIV treatment by government programmes. 
In addition to the reduction in human suffering, cost–
effectiveness analyses indicated that at the lower price at 
which tenofovir could be acquired, hepatitis B treatment 
would be cost-saving, with a return on investment of 
approximately US$ 1.3 for every dollar invested (71, 152). 
In 2017, China announced that the costs of hepatitis B 
treatment could be reimbursed by health insurance.
From economic analyses to fi nancial dialogue 
in Mongolia
The national viral hepatitis programme in Mongolia 
illustrates a comprehensive approach to fi nancing the 
hepatitis response, using economic analyses to advocate 
for adequate domestic funding, fi nancial protection for 
individuals to ensure access to services, and achieving 
affordable prices for hepatitis medicines (Fig. 9 and 
Box 5).
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BOX 5. INVESTMENT CASE LEADING TO REIMBURSEMENT FOR HBV AND HCV 
MEDICINES BY THE NATIONAL HEALTH INSURANCE IN MONGOLIA
Mongolia followed a sequential approach to fi nancing its hepatitis response. This included 
making an epidemiological assessment, modelling the future impact of interventions, 
identifying costs, conducting economic analyses, estimating the impact on the budget 
and holding a fi nancial dialogue between stakeholders. This dialogue was used to identify 
funding mechanisms to minimize out-of-pocket costs and determine whether the health 
sector could invest more in hepatitis or whether external funding sources would be needed. 
At the end of 2016, there were four generic companies and one originator company 
manufacturing HCV DAAs in Mongolia. Generic tenofovir costs US$ 84/year and generic 
DAAs (sofosbuvir/ledispavir) cost US$ 450/course. By the end of 2016, the Mongolian 
Government had included HBV and HCV medicines in the national health insurance, which 
covers 98% of the population. It reimburses individuals seeking treatment in both the public 
and private sectors. For HCV, around 60% of the cost is reimbursed (~US$ 265). However, 
this reimbursement is fi xed so the proportion of out-of-pocket expenses will decrease as 
wholesale prices come down. For HBV, 80% of the cost of generic medicines is reimbursed. 
During 2016, around 4000 people were treated for HBV, and around 8000 people for HCV in 
Mongolia. The cure rate for treatment of HCV infection was 92–99%. Overall, integration of 
the coverage of viral hepatitis services in the national health insurance illustrates the three 
dimensions of universal health coverage (Fig. 9).
19 – While there is a call for action to end hepatitis, funding available remains limited.
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Fig. 9. Viral hepatitis services in the three dimensions of universal health coverage in Mongolia
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PRICES OF MEDICINES
Prices of HCV medicines are falling but vary, 
and remain high in some countries
While the prices of DAAs against HCV recommended 
by WHO have decreased rapidly in some countries, they 
remain variable and are still unaffordable in others (153). 
In 2015, the US$ forex price (with a 23% rebate) for 
the combination of ledipasvir/sofosbuvir ranged from 
US$ 68 834 to US$ 655 (153). In October 2016, results 
of the analysis of data collected for the fi rst WHO global 
report on access to hepatitis C treatment indicated that, 
despite challenges, some pioneering low- and middle-
income countries were starting to deliver new hepatitis 
C treatment, reaching over one million in 2016 (102). 
Increasing generic competition is starting to lower the 
prices of DAAs, which are becoming more affordable. 
Prices remain high in high-income countries and those 
middle-income countries that do not have access to 
generic formulations and who fall outside of license 
agreements, placing a heavy burden on health systems 
and leading to treatment rationing. As of October 2016, 
the lowest price reported for a 28-day supply of sofosbuvir 
(Fig. 10 and Fig. 11) was US$ 300 in Pakistan and 
Rwanda from originator companies, and US$ 15–42 
in Pakistan from generic companies. The lowest price 
reported for a 28-day supply of daclatasvir was reported 
from Egypt; US$ 167 from the company that developed 
the medicine and US$ 7 from a generic company. 
Without lower prices, countries are unlikely to be able to 
increase investment to minimize the burden of hepatitis 
C. Sofosbuvir, daclatasvir and the sofosbuvir/ledipasvir 
combination, which are part of the preferred regimens 
in the WHO guidelines (54), are included in the 19th 
WHO model list of essential medicines and in the WHO 
prequalifi cation programme. However, as of March 2017, 
only one prequalifi ed generic formulation was available. 
There are opportunities for the public sector to optimize 
procurement of medicines (Box 6).
REDUCING THE PRICES OF COMMODITIES
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Fig. 10. Reported prices (originators and generics) for a 28-day supply of sofosbuvir in selected countries, per country income 
group (price information updated as of November 2016)
Fig. 11. Reported prices (originators and generics) for a 28-day supply of daclatasvir in selected countries, per country income 
group (price information updated as of November 2016) 
HIC: high-income country; LIC: low-income country; LMIC: lower–middle-income country; UMIC: upper–middle-income country
Source: Global report on access to hepatitis C treatment: focus on overcoming barriers. Geneva: World Health Organization; October 2016 (102)
HIC: high-income country; LIC: low-income country; LMIC: lower–middle-income country; UMIC: upper–middle-income country
Source: Global report on access to hepatitis C treatment: focus on overcoming barriers. Geneva: World Health Organization; October 2016 (102)
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Medicines for hepatitis B are available and 
inexpensive in most high-prevalence countries
Since 2015, the WHO treatment guidelines for hepatitis B 
(22) recommend antinucleos(t)ides with a high barrier to 
resistance as fi rst-line therapy for patients with hepatitis B 
who are eligible for treatment. In most patients that 
are eligible, the treatment is lifelong. Two medicines 
are available: entecavir and tenofovir. Entecavir is off-
patent, but availability and costs vary widely. Tenofovir 
is protected by a patent until 2018 in most upper–middle- 
and high-income countries, where the cost ranged from 
US$ 400 to US$ 1500 for a year of treatment in February 
2017. In most low- and middle-income countries, generic 
tenofovir produced by eight companies is available, 
and approved through the WHO prequalifi cation 
programme or tentatively approved by the United States 
Food and Drug Administration (USFDA). While some 
middle-income countries (e.g. Russian Federation, 
China) still face patent barriers in accessing tenofovir, 
generic tenofovir is affordable in most countries where 
it is accessible. The Global Price Reporting Mechanism 
(GPRM) indicates that the cost for a year of quality- 
assured treatment was US$ 48 in February 2017. 
Overall, tenofovir has the potential to be more widely 
used in the countries where it is available as a generic 
(Box 6). Ultimately, generic tenofovir should be available 
in all retail pharmacies. However, fears of reimportation 
in countries where the product is more expensive could 
be an obstacle to such distribution mechanisms until 
the patent expires.
BOX 6. OPPORTUNITIES TO OPTIMIZE PUBLIC SECTOR  PROCUREMENT OF  
MEDICINES FOR HBV AND HCV INFECTION
There are opportunities for the public sector to optimize the procurement of medicines 
against HBV and HCV infection at country level. Elements that can contribute to this 
optimization include:
Formulating national treatment guidelines that specify and recommend which medicines 
should be used; estimating the size of the infected population eligible for treatment; 
including medicines needed in the national essential medicines list; registering the 
medicines;a procuring and supplying hepatitis medicines through launching a tender to 
invite manufacturers to bid or purchasing through a pooled procurement mechanism.b
a  Including manufacturers of generic medicines if there is no patent or if the country is eligible for voluntary licensing
b  Examples include the strategic fund of the Pan American Health Organization and the Global Procurement Fund (GPRO fund, 
www.gprofund.org ) that negotiates prices for products and services based on a guaranteed volume. 
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PRICES OF DIAGNOSTICS
Although access to essential medicines for the treatment 
of persons living with hepatitis is improving, access 
to affordable, quality-assured diagnostics remains a 
barrier. The GHSS on viral hepatitis clearly spells 
out the need to reach out and test the population to 
identify asymptomatic persons living with viral hepatitis. 
However, this requires testing services and commodities. 
In a WHO-commissioned economic assessment of the 
cost of elimination, testing services accounted for a 
substantial share of the total cost (71,72). 
The price of serological tests used for the initial 
diagnosis of HBV and HCV infection is low
HBV. The reagent costs for HBsAg assays are similar 
for rapid diagnostic tests (between US$ 0.95 and US$ 
3.00) and laboratory-based assays (between US$ 0.40 and 
US$ 2.80). Machines that can handle high volumes of 
specimens in laboratories require additional infrastructure 
and equipment, and precision and expertise in operation. 
In contrast, rapid diagnostic tests do not require capital 
investment and can be performed by non-laboratory staff, 
such as trained health-care workers and lay providers. 
Up till March 2017, WHO had prequalifi ed a number 
of laboratory-based assays for HBsAg, but to date, no 
rapid diagnostic tests have met the WHO prequalifi cation 
requirements. A number of rapid diagnostic tests are 
unable to detect low levels of HBsAg, which limits 
their use for testing asymptomatic individuals. 
HCV. The cost of laboratory-based tests for HCV 
antibodies ranges from US$ 0.50 to US$ 1.70. 
As for HBV, they require laboratory infrastructure 
and equipment. The cost of rapid diagnostic tests for 
HCV antibodies ranges from US$ 0.50 to US$ 2.00 
for assays using capillary whole blood, and US$ 10 for 
assays using oral fl uids. As of March 2017, WHO had 
prequalifi ed a number of laboratory-based assays and 
two rapid diagnostic tests for HCV antibodies.
20 – Dispensing generic medicines in a public sector hospital, the Philippines. 
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Nucleic acid tests needed for treatment decisions 
are still expensive
The cost of tests that quantify the nucleic acids of HBV 
to make treatment decisions ranges from US$ 60 to 
US$ 200. The cost of the tests that quantify the nucleic 
acids of HCV to rule in HCV infection among individuals 
with HCV antibodies ranges from US$ 30 to US$ 200. 
The laboratory equipment needed for these nucleic acid 
tests is also expensive. They are operated by technicians 
with specialized training. Countries can reduce prices 
by using existing infrastructure and equipment that 
have been used to measure HIV viral load and detect 
tuberculosis. For HCV, another option would be to use 
a simpler test that detects HCV core antigen. The cost 
of testing for HCV core antigen ranges from US$ 25 
to US$ 50, which is comparable to qualitative HCV 
RNA testing (US$ 43–51). However, these high prices 
remain a barrier to large-scale use.
WHAT MECHANISMS WOULD SECURE 
FINANCING FOR ELIMINATION?
Given the limited availability of donor funds at the global level, most national viral hepatitis 
elimination plans will need to be funded through national resources. This will require a robust 
viral hepatitis investment case to advocate for adequate allocation of resources. Where appropriate, 
integration with other programmes should lead to opportunities for cost and programme 
effi ciencies. Optimized procurement of commodities through the public sector should also 
decrease cost, as medicines and diagnostics account for a large share of the cost.
A BLOOD TEST FOR AN 
INITIAL DIAGNOSIS OF 
HEPATITIS STARTS AT
US$ 0.5.
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INNOVATIONS FOR 
ACCELERATION
21 – Newer, more aﬀ ordable diagnostics 
is a high research priority.
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Major research and development 
innovations have transformed the 
fi eld of viral hepatitis in recent years. 
Pangenotypic HCV medicines are being 
introduced. Products that could further 
accelerate elimination include newer and 
cheaper point-of-care virological tests for 
HBV and HCV, a functional cure for HBV 
infection (aimed for by 2020–2025), and a 
vaccine for preventing HCV infection. 
KEY FINDINGS
These innovations in research and 
development need to be followed 
downstream and in sequence by (i) trials 
that evaluate new products for eﬃ  cacy, 
quality and safety to seek approval 
of products by national regulatory 
authorities, and (ii) fi eld assessments 
that evaluate the impact of introduction 
of new technologies on outcome and 
cost, so that innovations can reach the 
fi eld as quickly as possible.
1. RESEARCH AND DEVELOPMENT IS DYNAMIC
RECENT INNOVATIONS HAVE ENABLED THE 
COMMITMENT TO ELIMINATION 
Major innovations have occurred in the fi eld of viral 
hepatitis. For hepatitis C, innovations have transformed 
the fi eld and opened avenues previously thought 
impossible. New medicines for treating chronic hepatitis 
C infection have become available for use so rapidly 
that the fi rst WHO hepatitis C treatment guidelines 
released in 2014 (100) were updated in 2016 (54) and will 
be updated again in 2017. Other key recent innovations 
have included rapid serological tests that detect antibodies 
to HCV and point-of-care tests for the diagnosis of HCV 
infection (HCV RNA). Pangenotypic HCV medicines 
are being introduced progressively.
NEWER PRODUCTS COULD FURTHER 
ACCELERATE ELIMINATION 
Newer products that could accelerate elimination 
include newer and cheaper point-of-care rapid tests, 
including new ones for HBV DNA and affordable ones 
for HCV RNA, a functional cure for HBV (aimed for 
by 2020–2025) and a vaccine for preventing HCV 
infection. A functional cure for HBV infection could 
change the proportion of those infected who are eligible 
for treatment, with major consequences for elimination 
plans. In addition, there is a need for novel therapies for 
HDV coinfection as the net effect of HDV is to make 
the underlying HBV disease worse, including higher 
rates of cirrhosis and hepatocellular carcinoma. 
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2. TRIALS: INITIATIVES IN 
MIDDLE-INCOME COUNTRIES
3. FIELD ASSESSMENT
Trials evaluate the effi cacy, quality and safety of new 
technologies with a view to obtaining regulatory approval. 
This ensures that the new products work and are safe (Box 7). 
Through the support of UNITAID, fi eld assessment 
projects evaluate the impact of the introduction of 
new technologies on public health outcomes, cost and 
cost–effectiveness. For example, once a new diagnostic 
(such as a point-of-care test to measure HCV RNA) has 
been approved for use, its impact on increasing service 
coverage can be quantifi ed (e.g. by measuring how its 
use in the fi eld can lead to better diagnosis and linkage 
to care for injection drug users approached through 
outreach services).
BOX 7. A CLINICAL TRIAL IN MALAYSIA AND OTHER COUNTRIES TO EXAMINE 
OPTIONS FOR ALTERNATIVE TREATMENT OF HCV INFECTION 
Malaysia is working with the Drugs for Neglected Diseases initiative (DNDi) on a clinical 
trial (NCT02961426). This trial aims to facilitate the use of cheaper medicines suited to 
low- and middle-income country markets. It will assess the eﬃ  cacy and safety of a generic 
DAA (sofosbuvir) combined with ravidasvir, a new chemical entity, across all genotypes 
of HCV, among HCV-infected and HCV–HIV-coinfected persons. Shorter treatment 
schemes will be examined to facilitate future uptake and reduce cost. The treatment 
duration will be 12 weeks for subjects without cirrhosis and 24 weeks for subjects with 
compensated cirrhosis. Eﬃ  cacy will be judged on the basis of virological response 12 
weeks after completion of treatment. Similar trials are also planned in Thailand, South 
Africa and Viet Nam to obtain safety and eﬃ  cacy data across all genotypes. Ultimately, 
the data generated from these trials should be useful for the registration of this 
combination of medicines in these countries, which should facilitate procurement 
and open the way for use on a larger scale.
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4. LARGE-SCALE DISSEMINATION 
AND OPTIMIZATION
Prequalifi cation 
The WHO prequalifi cation system helps in increasing 
access to new medicines and diagnostics by assuring 
their quality and safety. As of March 2017, WHO had 
prequalifi ed a number of serological tests for HBV and 
HCV infection, two fi rst rapid diagnostic tests for HCV 
infection and generic tenofovir for the treatment of HBV 
infection. However, as of March 2017, only one generic 
DAA was prequalifi ed. Further work is needed to ensure 
the large-scale availability of prequalifi ed products.
Optimization
Research also includes work to optimize the use of 
technologies in health-care service delivery. Once 
diagnostics and medicines have been made available, 
the best service delivery models need to be identifi ed to 
improve service coverage and maximize health outcomes. 
Long-term follow up of treated patients 
New treatment protocols for HBV and HCV infection 
need to be evaluated also in the long term through cohorts 
of patients. This will allow assessment of the adverse 
effects of treatment on patients, risk of hepatocellular 
carcinoma after treatment, and prognosis after treatment 
of patients with advanced disease. 
HOW CAN INNOVATIONS ACCELERATE ELIMINATION?
• Generate innovative products through research and development. 
•  Evaluate new products for quality and safety in view of approval by national 
regulatory authorities.
•  Assess how new technologies improve health outcomes and reduce costs in the fi eld. 
•  Disseminate and optimize new commodities and monitor their impact in terms of 
long-term outcomes of patients.
INNOVATIONS FOR ACCELERATION
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THE ROAD TO 
ELIMINATION BY 2030
22 – Collaboration between the government, civil society, 
nongovernmental organizations and WHO facilitates 
strong national elimination plans.
Fig. 12. Global Health Sector Strategy on viral hepatitis: 2015 baseline towards the 2030 targets
a  Measurement of progress on HBV treatment target currently limited by the absence of data on the proportion of 
persons eligible and the absence of a functional cure 
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 1.  A GLOBAL PICTURE IS TAKING SHAPE BUT 
KEY DATA FOR ACTION ARE MISSING IN 
MANY COUNTRIES
In terms of strategic information, WHO 
is now in a position to formulate global 
and regional estimates for key indicators. 
However, many countries, lack data of 
suﬃ  cient quality. Strategic information 
systems that collect surveillance and 
programme data will guide elimination. 
2.  GAPS IN PREVENTION NEED TO BE CLOSED; 
TESTING AND TREATMENT NEED TO BE 
SCALED UP 
The elimination strategy has identifi ed 
the core interventions. Coverage gaps 
in prevention need to be closed, 
particularly for the birth dose of hepatitis 
B vaccine, health-care injection safety 
and harm reduction, if the target of 
90% reduction in new infections is to be 
reached. Rapid scaling up of testing and 
treatment is needed to reach the 65% 
mortality reduction component of the 
elimination target. 
3.  EXISTING OPPORTUNITIES NEED TO BE 
LEVERAGED USING A PUBLIC HEALTH 
APPROACH THAT REDUCES INEQUITIES
Recent years have been marked by an 
unprecedented increase in persons who 
access prevention and care services for 
hepatitis. However, this access has been 
fragmented and not equitable. Only a few 
countries have taken proactive steps to 
move towards elimination using a public 
health approach that benefi ts all those 
in need, including populations that have 
limited access to health services.
4.  SUSTAINABLE FINANCING OF ELIMINATION 
PLANS LEADS TO UNIVERSAL HEALTH 
COVERAGE 
Universal health coverage provides 
an overarching framework for health 
in the 2030 Agenda for Sustainable 
Development. This requires both strong 
health systems and disease-specifi c 
actions. An eﬀ ective hepatitis response 
will depend on the integration of hepatitis 
services into broader health programmes 
and funding through adequate national 
health budgets. Hence, the focus needs 
to be on improving the eﬃ  ciency, reach 
and quality of hepatitis services, on 
reducing prices, and on optimizing the 
procurement of commodities for testing 
and treatment of hepatitis. National 
health budgets need to cover the costs, 
and ensure relevant services without 
fi nancial hardship to the patient. 
5.  A DYNAMIC RESEARCH AGENDA LEADS TO 
NEW PRODUCTS AND APPROACHES 
Research in the fi eld of viral hepatitis 
has been highly active, generating 
new products at a rapid pace. Further 
innovation is needed to optimize 
vaccines and other prevention 
interventions, diagnostics, medicines, 
and models of service delivery, with a 
focus on improving eﬃ  cacy, quality, 
safety and access, and eﬃ  ciently 
documenting and achieving public health 
impact. Priorities include rolling out 
pangenotypic medicines for HCV and 
developing newer and cheaper point-
of-care tests, including for HBV DNA. 
In the future, a functional cure for HBV 
and, ultimately, a vaccine against HCV 
infection would complete the set of tools 
available for elimination. 
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GENERAL APPROACH 
DATA COLLECTION AND ANALYSIS
WHO used systematic methods to generate the evidence 
consolidated in this global report on viral hepatitis. 
The Reference Group for Strategic Information and 
Modelling advised WHO on the scope of the report, its 
technical content and the epidemiological methods used. 
This included the use of Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER) (154) 
checklist. The WHO department of Information, Evidence 
and Research systems reviewed and cleared the report.
MORTALITY
To estimate the current mortality due to past infections, 
we used WHO global health estimates methods based 
on the “mortality envelope” (2). In short, the proportion 
of sequelae (cirrhosis and hepatocellular carcinoma) 
attributable to HBV and HCV infections was applied 
to the mortality data from these sequelae obtained from 
vital registration services and modelling (68, 155). 
All WHO global health estimates data are available from 
the WHO Internet site at: http://www.who.int/gho/
mortality_burden_disease/en/. 
PREVALENCE AND INCIDENCE OF HBV INFECTION
WHO commissioned the London School of Hygiene 
& Tropical Medicine (LSHTM) to generate estimates 
of the prevalence and incidence of HBV infection. 
LSHTM investigators conducted a systematic review of 
all biomarker surveys that estimated the prevalence of 
HBsAg in the general population before implementation 
of vaccination, and in children under 5 years of age
after vaccination. To generate estimates in countries and 
territories without empirical data, modellers extrapolated 
the available data using mathematical models on the basis 
of geographical proximity to countries that had data, 
and income levels. In the absence of better data, the 
prevalence of HBsAg among children under 5 years of 
age was used as a surrogate indicator of the cumulative 
incidence of chronic HBV infection at fi ve years of age (8). 
This represents a slight variation from the core indicator 
of the monitoring and evaluation framework 
of the GHSS on viral hepatitis (8).
PREVALENCE AND INCIDENCE OF HCV INFECTION
WHO commissioned the Center for Disease Analysis 
(CDA) to generate estimates of the prevalence and 
incidence of HCV infection. The CDA conducted a 
systematic review of biomarker surveys estimating the 
prevalence of HCV infection (53). On the basis of the 
prevalence data, investigators constructed a country-by-
country HCV infection model that predicted incidence 
and prevalence. In-country experts reviewed these 
models and provided comments and suggestions on 
the process, and on the outcome. Estimates for countries 
and territories without empirical data were extrapolated on 
the basis of Global Burden of Disease regional averages.
CASCADE OF CARE FOR HBV AND HCV INFECTION
WHO commissioned the CDA for estimates of the 
cascade of care. Investigators modelled estimates of 
the cascade of care for HBV and HCV infection using 
country-level models, sales of medicines, expert opinions 
from national stakeholders and extrapolations.
PREVENTION INDICATORS 
To estimate the coverage of prevention interventions, 
sources of data included vaccine coverage reported to 
WHO and UNICEF (156), data on the coverage of 
screening of blood donations reported to WHO in the 
Global Database on Blood Safety (80), systematic reviews 
that estimated the frequency of unsafe injections (40), 
and coverage of harm reduction indicators (93).a
ANNEX 2. HOW WERE THESE ESTIMATES GENERATED?
ALSO SEE THE METHODOLOGICAL ANNEX AVAILABLE ONLINE AT:  
http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ 
ANNEX 2. HOW WERE THESE ESTIMATES GENERATED?
a  The original GHSS indicator is the on the use of injection devices with reuse prevention features. In the absence of data on this indicator, data are presented on the 
proportion of unsafe injections with targets at 0% for 2020 and 2030.
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COUNTRY INTELLIGENCE 
To update the previous policy report (157), WHO 
collaborated with the World Hepatitis Alliance to 
approach Member States and generate “country profi les”. 
These examined inputs, processes and outputs that 
described the status of implementation of the GHSS on 
viral hepatitis, including the availability of a national 
viral hepatitis plan.
ROLE OF INJECTION DRUG USE IN THE EPIDEMIC 
OF VIRAL HEPATITIS
New infections. To estimate the proportion of new HBV 
and HCV infections attributable to injection drug use, 
we used the fraction of disability-adjusted life-years 
(DALYs) from acute HBV and HCV infections 
attributable to injection drug use in the Global Burden 
of Disease study, 2013 (107).
Chronic infections. To estimate the proportion of chronic 
HBV and HCV infections among persons who currently 
inject drugs, we extracted the prevalence of HBsAg 
and anti-HCV among persons who inject drugs (108), 
adjusted for the proportion of anti-HCV-positive persons 
who have HCV infection (53), multiplied this prevalence 
by the 2015 estimates of the number of people who inject 
drugs worldwide, and divided this estimated number of 
people who inject drugs with HBV and HCV infection 
by the total number estimated by WHO of HBV and 
HCV infections worldwide.
Deaths. To estimate the proportion of deaths from the 
sequelae of HBV and HCV infections attributable to 
injection drug use, we applied the fraction of HBV- 
and HCV-induced cirrhosis and hepatocellular carcinoma 
attributable to lifetime injection drug use from the Global 
Burden of Disease study (107) to the 2015 WHO global 
health estimates for mortality available from the WHO 
Internet site (http://www.who.int/gho/mortality_burden_
disease/en/). 
WHY AND HOW DO WORLD HEALTH ORGANIZATION 
ESTIMATES CHANGE?
Estimates formulated or quoted by WHO evolve 
over time. In general, this is due to improvement in 
criteria, availability of higher-quality data, improved 
review methods and stronger analysis techniques. 
This report contains new or updated estimates from 
WHO. Key changes and updates are given in the 
following paragraphs.
HBV ESTIMATES
In the past, WHO estimated that there were 240 million 
persons with HBV infection in the world (125). The new 
estimate (257 million) is not far from the previous one. 
It refl ects that more data have been made available, that 
more complex methods have been used (modelling) and 
that the size of the population has been increasing.
HCV ESTIMATES
WHO had not formulated estimates of the number 
of persons living with HCV before. However, WHO 
quoted a number of publications that were based on the 
use of anti-HCV (serological evidence of past or present 
infection) (158) rather than HCV RNA (evidence of 
HCV infection). Use of HCV RNA as a criterion to defi ne 
HCV infection is a better refl ection of the public health 
implications of the HCV epidemic and explains a decrease 
in the estimates. A 2014 study estimated that 80 million 
persons were living with HCV infection (159). The 2015 
estimate published by WHO in this report in 2017 (71 
million) is a small adjustment that refl ects the availability 
of better data from large countries that substantially 
infl uence the global estimates. 
MORTALITY ESTIMATES
For many years, WHO did not have a mechanism to 
count deaths from cirrhosis and hepatocellular carcinoma 
associated with HBV and HCV infection. As methods 
evolved to measure the proportion of cirrhosis and 
hepatocellular carcinoma associated with HBV and HCV 
infection, estimates have also progressively evolved. For 
the GHSS on viral hepatitis, WHO quoted estimates 
from the Global Burden of Disease (1.46 million deaths 
in 2013) (155). The new estimate has been formulated 
by WHO (1.34 million deaths). It takes into account a 
recent publication on the proportion of hepatocellular 
carcinomas that are attributable to HBV and HCV 
infection (68). The WHO estimate for 2015 is slightly 
lower than the one previously used but the trends over 
time, estimated retrospectively, are on the increase. 
The new estimate also correctly identifi es the relative 
proportion of deaths attributable to HBV and HCV 
infections. The proportion of deaths from HBV is 
now higher than the proportion of deaths from HCV. 
These changes are explained mostly by the remaining 
areas of uncertainty regarding the fraction of cirrhosis 
and hepatocellular carcinoma attributable to HBV and 
HCV infections versus other causes of chronic liver 
disease, such as alcohol or the metabolic syndrome. 
While the exact number of deaths for a given year may 
change according to the methods used, an upward trend 
in mortality is seen, irrespective of the method used (155).
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A FRAMEWORK TO REPORT ON THE GLOBAL STRATEGY 
AND FROM A COUNTRY PERSPECTIVE 
THE FIVE STRATEGIC DIRECTIONS OF THE GLOBAL 
HEALTH SECTOR STRATEGY ON VIRAL HEPATITIS 
We structured this report as per the fi ve strategic 
directions of the 2016 GHSS on viral hepatitis, which fi ts 
in with the context of the 2015 Sustainable Development 
Goals (SDGs, Target 3.3) (16, 160). This framework 
is relevant for comprehensive reporting on the global 
progress of the GHSS on viral hepatitis.
THE 10 CORE INDICATORS OF THE MONITORING 
AND EVALUATION FRAMEWORK FOR VIRAL 
HEPATITIS B AND C
WHO prepared a monitoring and evaluation framework 
(8) for viral hepatitis B and C. This follows the result 
chain, from (a) context and needs (indicator C.1 on 
prevalence) to (b) input (indicator C.2 on testing 
capacity), (c) output and outcomes (indicators C.3–C.5 
on prevention, and indicators C.7–C.8 on the cascade 
of care), and (d) impact (indicator C.9 on incidence and 
indicator C.10 on mortality). This framework is adapted 
more to reporting at the country level and was not used 
for the policy report.
CASCADE OF CARE
The GHSS on viral hepatitis was published in 2016 (7). 
It contained approximations in terms of the proportion 
of infected persons diagnosed, treated, and virologically 
suppressed or cured. These were not based on systematic 
reviews. In this report, WHO for the fi rst time makes 
an attempt to use the best possible data available to 
estimate the cascade for HBV and HCV infection. 
These estimates are imperfect because the data systems 
that should generate them are not in place in most 
countries. The quantity and quality of data available 
are better for HCV than for HBV. In some regions, 
such as the African Region, data are particularly scarce. 
Therefore, WHO will continue to collect more data 
of better quality in order to update and refi ne these 
estimates.
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REMAINING AREAS OF UNCERTAINTY
This fi rst-ever global report on viral hepatitis describes 
what is known of the current status of viral hepatitis 
in the world. However, data systems are not in place in 
many parts of the world to generate the necessary strategic 
information. Limitations explain why this initial report 
provides estimates only at the regional level. They also 
point to the need for stronger mechanisms to collect, 
transfer, analyse and disseminate data on viral hepatitis.
MORTALITY IS POORLY MEASURED IN ROUTINE 
REPORTING AT THE NATIONAL LEVEL
Methods to estimate mortality use a combination of data 
from two types of sources. First, the “mortality envelope” 
from the vital registration, and second, the “attributable 
fraction” generated by clinical centres. At the global level, 
this method has been adopted by the Global Burden of 
Disease, the International Agency for Research on Cancer 
(68) and WHO. Routine systems are needed to measure 
this attributable fraction at the country level and to link 
these data with “mortality envelope” data so that in the 
future, sound, robust estimates can be generated, which 
can be accepted by all partners involved.
SOME COUNTRIES STILL LACK POPULATION-
BASED ESTIMATES OF THE PREVALENCE 
OF INFECTION
Biomarker surveys are the reference epidemiological tool 
for estimating the prevalence of HBV and HCV infection. 
These prevalence estimates are key for planning testing 
and treatment. However, in the body of evidence that 
led to this report, reliable population-based estimates 
of the prevalence of HBV and HCV infection were 
available only from some countries. In others, regional 
averages or other sources of data were obtained through 
the use of extrapolation techniques. While the absence of 
information on the prevalence of HBV or HCV infection 
in a country is unlikely to affect global estimates to a large 
extent, they can prevent the engagement of stakeholders 
at the national level. Hence, countries that do not have a 
national, population-based estimate of the prevalence of 
HBV and HCV infection may need to consider planning a 
biomarker survey (see Box 1, page 18). This is particularly 
relevant in Africa where the impact of the third dose 
of hepatitis B vaccine in the absence of a timely birth 
dose is poorly understood because of a lack of biomarker 
surveys. WHO has developed template protocols for these 
biomarker surveys, which are available upon request.
KEY PREVENTION MEASURES ARE POORLY 
MONITORED
Two health interventions are particularly critical for the 
prevention of HCV infection: safe and appropriate use of 
injections, and harm reduction. However, service coverage 
for these two interventions is poorly monitored.
Monitoring health-care injection safety is still based 
on ad-hoc surveys
With respect to health-care injection safety, two methods 
are available to estimate the proportion of injections 
that are given with syringes and needles reused without 
sterilization. The fi rst is based on population surveys 
where individuals selected in samples recall during an 
interview the circumstances of the last injection that they 
received (40). The second is based on surveys of health-
care facilities during which evaluators attend health-care 
facilities and inspect injection techniques (161). None of 
these methods are easy to use routinely for monitoring. 
Hence, the proportion of injections that are unsafe 
remains a poorly measured indicator and global estimates 
need to rely on systematic reviews of surveys done ad hoc. 
Harm reduction indicators suffer from data gaps
While UNAIDS collects data from critical indicators 
on harm reduction in the context of the Global AIDS 
Response Progress Monitoring (GARPR) (162), systems 
to routinely collect, transmit and analyse data to provide 
feedback on indicators for measuring harm reduction are 
still weak. As a result, global estimates are not updated 
regularly and are based on systematic reviews of ad-hoc 
studies that have gaps (93).
THE INCIDENCE OF HCV INFECTION IS 
TECHNICALLY DIFFICULT TO MEASURE
Measuring the incidence of HCV infection is technically 
diffi cult. Most methods rely on mathematical models. 
However, modelling the incidence of HCV infection 
poses several methodological challenges. First, new HCV 
infections are most often asymptomatic (163). Second, 
there is no biomarker that can be used to identify recent 
HCV infection (164). Third, the incidence of HCV 
infection is probably low from a statistical point of view, 
which complicates measurement with precision because 
of the small sample size (150). As a result, this report 
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publishes modelled estimates of incidence that suffer 
from substantial uncertainty and are not validated in 
most countries. Trends in incidence identifi ed through 
modelling need to be verifi ed using surveillance data, 
albeit with some limitations. Data from surveillance for 
acute hepatitis C, which refl ect new infections, are useful 
for this validation. The number of cases of acute hepatitis 
C is underreported as a large proportion of infections are 
symptomatic. However, when considered in light of these 
limitations, the reported number of cases of acute hepatitis 
C provides information on time trends that are hard to 
obtain from other data sources. In the United States, 
surveillance for acute hepatitis C showed a re-emergence 
of new HCV infections associated with injection drug use 
in rural areas (45).
SYSTEMS TO MONITOR THE CASCADE OF CARE 
ARE STILL BEING ESTABLISHED 
Most of the data used in this report to estimate the 
cascade of care for HBV and of cure for HCV are 
based on a variety of ad-hoc sources that are often cross-
sectional. WHO is in the process of providing countries 
with standardized tools to set up patients’ databases, 
which could be used to generate estimates for these core 
indicators of the cascade of care. As a result, estimates 
of the cascade of care in this report should be considered 
as preliminary. They should be used with caution and, 
in the future, ad-hoc sources of information should be 
replaced by data obtained from patients’ databases.
THE CAPACITY TO TEST FOR HBV AND HCV 
INFECTION AT COUNTRY LEVEL IS UNCLEAR 
One of the most challenging service coverage targets of 
the GHSS on viral hepatitis is to increase the proportion 
of those infected who are diagnosed (30% by 2020 and 
90% by 2030) (7). This will require a substantial increase 
in the capacity to test individuals for viral hepatitis, 
which will require investment in resources and capacity 
for in-vitro diagnosis. Hence, among other inputs to the 
response to viral hepatitis that can be considered (e.g. 
governance, essential medicines, service delivery models, 
fi nancing), the core indicator selected by WHO as part 
of the monitoring and evaluation framework for viral 
hepatitis is the infrastructure for testing for HBV and 
HCV infection (8). Core indicator C.2 monitors the 
infrastructure for HBV and HCV testing. It is defi ned as 
the ratio of facilities with the capacity to test individuals 
for chronic hepatitis HBV and/or HCV per 100 000 
population according to molecular methods (HCV 
RNA, HBV DNA) and serological methods (HBsAg, 
anti-HBc, anti-HCV). This indicator is structured like 
other indicators that estimate the capacity for laboratory 
diagnosis for the SDGs (8). It can be measured through 
health-care facility surveys, such as the Service Availability 
and Readiness Assessment (SARA) tool in the future 
(165). However, data are not yet available, and thus in 
2015, the capacity for countries to test for HBV and 
HCV infection remains unclear.
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